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ABSTRACT 
INTRODUCTION: Following ambulatory surgery, rapid return of cognitive function is 
imperative. Data on the recovery of cognitive function after low dose midazolam 
coinduced general anesthesia is limited. It is unknown if coinduced general anesthesia 
allows faster return of function due to lower total drug dosages or prolongs cognitive 
recovery due to benzodiazepine effects. This study uses neuropsychological testing to 
measure cognitive recovery after midazolam coinduced anesthesia compared to propofol 
induced controls in ambulatory gynecology patients undergoing short laparoscopic 
procedures. 
METHODS: With approval of the hospital research ethics board, 88 eligible patients 
were randomized in a double blind manner into one of two groups; propofol 2mg/kg 
control (n=44) or midazolam 0.02mglkg with propofollmg/kg coinduced group (n=44). 
All patients received a standardized general anesthetic including endotracheal intubation. 
Neuropsychological objective testing consisted of a Digit Symbol Substitution Test 
(DSST), a Trieger Dot Test (TDT) and five Visual Analogue Scales (VAS) for subjective 
assessment of anxiety, sedation, coordination, confusion and drowsiness. Tests were 
completed preoperatively and postoperatively every 30 minutes until discharged. 
Intraoperative variables (including adverse events, hemodynamics), time to discharge, 
Post Anesthesia Care Unit (P ACU) narcotic and anti-emetic use were recorded. 
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RESULTS: At 60 minutes postoperatively, 84 of the 88 subjects had complete data sets. 
Statistical significance was not reached (all p's >0.05) on tests of postoperative 
neuropsychological recovery comparing the propofol control group and the midazolam 
coinduced group. The groups had clinically similar scores on the VAS testing, DSST 
(51.8+/-12.7 vs. 55.7+/- 10.5 p=O.l2, 95%CI -9.01 to 1.11 to detect a difference of 13.8) 
and TDT (7.9+/-7.3 vs. 7.1+/- 5.8 p=0.56). The DSST, TDT and VAS data were further 
analyzed using repeated measures ANCOV A to compare groups over time (with baseline 
preoperative test scores as covariate) and no significant difference (DSST p = 0.78) was 
found based upon group randomization. There was no significant difference in 
intraoperative hemodynamic parameters, the incidence of adverse events (3 (7 .1%) vs. 
2(4.8%)); failed induction (5(11.9%) vs. 5(11.9%)); length ofPACU stay (1 :31 +/-37 vs. 
1:23+/-32 min); PACU morphine (0.13+/-0.10 vs. 0.13+/-0.11mg/kg); ondansetron 
rescue (13(31 %) vs. 12(28.6%)). There was no intraoperative awareness in either group. 
DISCUSSION: Midazolam in a low dose (0.02mg/kg) used as a component of 
coinduced general anesthesia for short ambulatory procedures does not appear to alter 
cognitive recovery as measured by neuropsychological testing compared to standard 
propofol (2mg/kg) induction. Intraoperative and P ACU variables also appear to be 
similar between techniques. Thus, there is no disadvantage in recovery characteristics 
nor does there appear to be any advantage or disadvantage with respect to hemodynamic 
stability, quality of induction or drug cost. Due to rarity of intraoperative recall, we 
cannot conclude if midazolam is protective. 
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CHAPTER! 
Introduction 
SCIENTIFIC BACKGROUND 
Intravenous Anesthetic Induction Agents 
Intravenous anesthetic induction agents rapidly cause the loss of consciousness or 
the induction of hypnosis I sleep upon patients undergoing general anesthesia. These 
drugs are thought to potentiate the activity of the gamma-aminobutyric acid (GABA) at 
the GABA receptor in the central nervous system (1). This neurotransmitter is the 
principal inhibitory neurotransmitter within the central nervous system (CNS). The 
GABA receptor exists as a receptor complex (figure #1.1) -the GABA receptor, chloride 
ion channel, barbiturate binding site and a benzodiazepine binding site (1 ,2). When the 
GABA receptor is activated, the transmembrane chloride conductance increases which in 
turn results in hyperpolarization of the post-synaptic cell membrane. This results in 
functional inhibition of the post-synaptic neurone. The binding of an intravenous 
induction agent to its specific sub-unit within the GABA receptor complex will decrease 
the rate of dissociation of GABA from it's receptor, thereby increasing the duration of the 
GABA mediated opening of the chloride channels. The resulting inhibitory cell 
membrane hyperpolarization is presumed to be how these agents exert their sedative-
hypnotic effects (2). 
ExtraceUular 
lon channel Intracellular 
Figure# 1.1 GABA Receptor Complex- with 
receptor sub-units a I ~ I BDZ within the 
complex (BDZ = benzodiazepine) 
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The ideal intravenous induction agent needs to be potent, with rapid onset, 
relative short duration of action and have rapid, complete recovery even after prolonged 
administration. There should be little therapeutic variability i.e. predictable onset I offset 
of action. There should be minimal cardiovascular and respiratory depressant side effects. 
It should allow rapid recovery with minimal postoperative side effects such as nausea and 
vomiting, headache, prolonged sedation " hangover" or cognitive effects. There should 
be inactive non-toxic metabolites with metabolism and excretion independent of the liver 
and kidneys. Such agents must have a relative lack of side effects including minimal 
histamine release, allergic reactions, and alterations of intracranial pressure or teratogenic 
potential (1 ). The drug dose that is suggested for use in the induction of general 
anesthesia is the ED 50 (3). The ED 50 of an anesthetic induction agent is the Estimated 
Dose of that drug that will reliably induce hypnosis in 50% of patients. 
Several classes of anesthetic induction agents are used in clinical practice. 
Barbiturates - derivatives of barbituric acid 
i.e. methohexital, sodium thiopental, thiamylal, 
pentobarbital 
Carboxylated imidazoles- etomidate 
Jsopropophenols- propofol 
Phencyclidine derivatives- ketamine 
Progestrone derivatives- eltanolone 
First introduced into clinical practice in 1934, sodium thiopental (Pentothal®) is a 
thiobarbituarate derivative ofbarbituric acid (4). Thiopental was the first widely used 
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intravenous anesthetic induction agent and has been used almost exclusively for over 50 
years. Thiopental is still accepted and used in clinical practice. Sodium thiopental was 
the historic gold standard to which all other newer intravenous induction agents are 
compared (1,4). Sodium thiopental is not an ideal intravenous anesthetic agent. New 
drugs, within the barbituric acid class as well as others have been developed and 
introduced into clinical practice in the past three decades. These new drugs strive to meet 
the ideal pharmacological criteria. Newer intravenous induction agents include ketamine 
(Ketalar®), methohexital (Brietal®), etomidate (Amidate®) and propofol (Diprivan®) 
(1,4). 
Intravenous benzodiazepines such as diazepam and midazolam have been used as 
anesthetic induction agents. Benzodiazepines compared to standard intravenous 
induction agents (i.e. thiopental, propofol) are slow with respect to onset and are 
unpredictable due to wide variation in dose response relationship (1,4). Compared to 
other standard intravenous induction agents benzodiazepines have a prolonged recovery 
i.e. time to return to consciousness and time to orientation (1 ,4,5). Midazolam, a newer 
water soluble benzodiazepine is slightly more rapid in onset, with a shorter elimination 
half-life compared to older drugs such as diazepam. Midazolam 0.15-0.2mg/kg (ED50 
for induction) was initially felt to be an acceptable induction agent. Compared to 
diazepam it had a more rapid onset and recovery but when compared to thiopental or 
propofol it was still inferior as an intravenous induction agent ( 4,5). Benzodiazepines 
therefore are not used routinely as intravenous anesthetic induction agents (1,4). 
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Propofol, the most recently introduced anesthetic induction agent is a novel 
intravenous induction agent not related to any other class of intravenous induction agent. 
Propofol was developed and introduced into clinical practice between 1986-1989. 
Propofol has gained acceptance and popularity in clinical practice during the past decade. 
The use of propofol now surpasses sodium thiopental, despite similar induction qualities 
and greater expense. Since its introduction, Astra-Zeneca, the proprietary owners of 
Diprivan® (propofol) estimates propofol has been used in over 330 million patients. 
The supremacy of propofol over other induction agents including the barbiturates 
in part comes from its recovery characteristics. Propofol induced anesthesia recovery is 
associated with faster eye opening, faster time to discharge, improved cognitive function 
and less post-operative nausea and vomiting. Propofol therefore is felt to be a better 
intravenous induction agent for the ambulatory surgery patient (6-10). Propofol it is now 
considered the gold standard (4) to which all other agents are compared. Generic 
formulations of propofol now available have reduced cost allowing more routine use. 
Despite this propofol is not an ideal intravenous anesthetic agent. Propofol is still more 
expensive than thiopental, causes moderate pain on injection in a large proportion of 
patients, supports bacterial growth and may cause profound bradycardia I asystole on 
induction (4). 
Unfortunately there is no ideal intravenous induction agent. The newer agents 
have incorporated some of the characteristics of the ideal agent but each fails in areas 
where other induction agents succeed. Depending upon the specific drug, the various 
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agents all have advantageous and deleterious pharmacological properties that may make 
them more or less desirable for a specific clinical situation. When deciding upon which 
agent to use, the anesthesiologist must consider these characteristics ( 1). 
Drug Synergy 
Synergistic drug interactions occur when the effect of a drug combination is 
greater than the sum of the individual components i.e. the effect is supra-additive (11). 
Interactions between biologically active agents are important, as the combined effect may 
offer therapeutic advantages over single agents (e.g. combination chemotherapy). 
Modern anesthetic techniques usually utilise these interactions using a "balanced 
anesthetic technique". This involves deliberate poly-pharmacy to maximise the desired 
drug effects and to minimise undesired drug effects. The term "coinduction" was first 
used to describe the unplanned induction of general anesthesia by non-anesthetic 
personnel providing sedation utilising benzodiazepines and narcotic agents in unsuitable 
environments (12). 
Subsequent investigations using isobolographic analysis documented drug 
synergy when combining anesthetic agents (thiopental: morphine I propofol: fentanyl I 
thiopental: midazolam I propofol: midazolam I midazolam: alfentanil etc) both in animals 
and humans (13-21). Specific interest developed in evaluating "coinduction" or 
synergistic drug interactions for induction agents with narcotics and I or benzodiazepines. 
Isobolographic analysis provides a precise means of measuring drug interactions. 
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On an isobole diagram (see figure #1.2), points on the X andY axes (usually representing 
the potencies (ED 50) of each of the two drugs when used alone) are joined by a straight 
line. This line defines the fractional combinations of the two agents that would be 
expected to have this same potency if the interaction between the two agents was 
additive. If the reference point (i.e. ED 50 for anesthetic induction agents) of a 
combination of two agents falls significantly to the left of this additive straight line, a 
synergistic interaction between the two agents is inferred. If the interaction lies to the 
right above the straight line then a presumed drug antagonism occurs. 
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Synergism 
N 
0) 
:::J 
... 
0 
0 
C\1 
0 
0 
c 
0 (J 
Isobologram 
Antagonism 
Cone c1 of Drug 1 
Figure #1.2 Isobologram of Drug Interactions. Additive 
drug interactions fall on the straight line. Synergy occurs if 
the drug effect lies to the left of the line and antagonistic 
interaction when it is to the right 
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Kissen et al (14) initially demonstrated a 75% dose reduction for midazolam and a 
75% dose reduction for sodium thiopental when given in combination to rats. The 
biologic basis for this potentiation is thought to occur via the benzodiazepine sub-unit on 
the GABA receptor complex (18)(see figure #1.1). Various combinations of agents 
(thiopental, propofol, alfentanil, morphine, midazolam etc.) and the degree of drug 
synergy were studied and documented using isobolographic analysis (15,17,18,22-24). 
Isobolographic analysis of midazolam and propofol indicates that there is drug 
synergy with the ED50s falling left ofthe line of additivity. There are various equipotent 
ED50 drug dosage combinations along the ED50 isobol that could be used to produce 
hypnosis comparable to propofol ED50 of2mg/kg (see figure#1.3). Referring to figure 
#1.3, the dashed lines show two combinations, with the X andY intercepts being the 
individual drug doses to be used in the combination. 
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MIDAZOLAM-PROPOFOL SYNERGISM. 
1.4 
1.2 
-1 r 0.8 
~ . 
Q. 0.6 
e 
D. 
0.4 
0.2 
0 
0 
1/10 
0.05 0.1 
X 
10/10 
0.15 
Midazolam (mg kf1) 
0.2 0.25 0.3 
ED 50 lsoboloaram for rnidazo.lam-propofol combination as predicted. by the probit interaction model (labelled 
ED50 isobol) for the clinical end~point1 loss of response ro oommand. The equation for this curve is: 
6.86X + 1.43 Y + 18. 79XY -1.93 = 0; where X and Y are the doses of mid.uolam and propofol, respectively. 
Successful induction rates for the nine drug combinations studied in phase 2 are shown. Midazolam-propofol 
combillations referred to in the text are denoted by dorted lines. 
Figure#1.3 Isobolographic Analysis ofMidazolam-Propofol. The diagram 
shows numerous possible synergistic combinations (McClune et al) 1 
1 McClune,S., McKayA.C., eta! Synergistic interaction between midazolam and propofol. British Journal 
of Anaesthesia 1992;69:240-245 
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Anesthetic Coinduction Technique 
Taking advantage of drug synergy numerous studies in man have confirmed that 
induction of general anesthesia could be reliably accomplished using a much lower total 
drug dosage (14-24). The term "coinduction technique" was adopted for concurrent 
administration of two or more drugs utilising drug synergy to facilitate induction of 
general anesthesia. The combination of propofol and midazolam became one of the most 
commonly used "coinduction techniques". The synergistic drug effect allowed much 
smaller total drug dosages to be utilised during induction of general anesthesia, yet the 
same clinical end point of hypnosis was achieved. 
As indicated by figure # 1.3 there are various synergistic drug combinations for 
propofol and midazolam. Vinik (25,26) suggested using the combination of midazolam 
0.02mg/kg (one-tenth the usual induction dose ofmidazolam 0.2mg/kg), which was to be 
injected two minutes before lmg/kg propofol (one halfthe usual induction dose of 
propofol). This "coinduction technique" suggested by Vinik gained popularity in mid 
1990's. This was in part due to strong marketing by Hoffman-LaRoche Ltd. who held 
the patent for midazolam (proprietary name-Versed®). It was also striving to achieve the 
"ideal" intravenous induction agent. Coinduction using synergistic drug interactions of 
propofol and midazolam was expounded as the latest "ideal" agent. The use of propofol 
and midazolam in a "coinduction teclmique" became the principal induction teclmique 
for ambulatory I day case patients. Numerous benefits of coinduction were hypothesised 
but few had been proven. 
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Proponents of the coinduction technique (25-29) proposed that there should be 
less cardiovascular depression with improved hemodynamic stability and less respiratory 
depression with lower total drug dosages. Possible other hypothesised benefits included 
faster recovery, time to eye opening and possible earlier discharge. The current move for 
health care cost containment made pharmacoeconomic savings due to smaller total 
dosages and possibility of earlier discharge attractive possible benefits of coinduction 
(29). 
Improved Surgical Outcome 
During the 1980's and early 1990's surgery underwent a revolutionary change 
(30). Introduction of minimally invasive techniques, newer approaches to postoperative 
pain management and focus on early mobilisation allowed more elective operations, 
including more extensive surgeries to be done on ambulatory patients. Advances in 
anesthetic techniques including development of rapid short acting volatile anesthetics, 
opioids and muscle relaxants facilitated this change. 
More surgical patients were undergoing "ambulatory" procedures and discharged 
home after the surgical procedure. Further-more, patients undergoing short, minor 
surgical procedures were being "fast tracked"- discharged 30 minutes post general 
anesthesia without going to a post anesthesia care unit (PACU). Ultimately, more 
patients are going home, going home earlier, and going home after much larger surgeries. 
This philosophic change in health care delivery and in perioperative care was felt to be an 
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improvement in overall surgical outcome and patient care (6). This trend was fuelled 
also by increasing health care costs and the efforts of health care managers to contain 
them. There were definite economic benefits to operating room budgets with fewer 
hospital admissions, earlier discharge and "fast tracking". There was a definite need for 
ambulatory patients to be "discharge ready" and "street ready" as early as possible. 
Optimization of anesthetic technique and especially the recovery characteristics of 
general anesthetics became more important to anesthesiologists and health-care 
managers. Ultra short acting drugs were developed and marketed for general anesthesia 
in ambulatory patients. The recovery characteristics of anesthetic induction agents now 
became as important as the induction qualities. Many studies looked at the recovery 
characteristics of the various intravenous induction agents i.e. sodium thiopental, 
methohexital, propofol, diazepam, midazolam etc. (5,7,8, 31-38). 
Anesthesia Recovery 
The recovery period or time after administration of general anesthesia is broken 
down into several time intervals. Early recovery may be defined as the time interval when 
patients emerge from anesthesia, are recovering protective reflexes and motor activity. 
This may be a period of altered physiologic function and hemodynamic instability. 
Intermediate recovery is the period when level of consciousness, co-ordination and 
physiologic function has normalised. Late recovery therefore is when the patient is fully 
back to preoperative function and has return of normal behaviour or cognitive function. 
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Early stages of recovery after general anesthesia can be assessed by one of two 
ways. First, by noting the time that .fixed events occur i.e. time to eye opening, time to 
extubation, time to obey commands and I or time to discharge. Alternatively recovery 
may be evaluated at .fixed times using a scoring type system i.e. the Glasgow Coma Scale, 
the Aldrete-Kroulik Post Anesthetic Recovery Score or the Stewart Score (39). The 
Aldrete Score introduced in 1970, is a commonly used score during admission to Post 
Anesthesia Care Units (P ACU) to assess physiological function. This and other scoring 
systems were designed to convey objective information about the physical condition of 
patients admitted to P ACU after an anesthetic. The Aldrete Score evaluates level of 
consciousness, activity, respiration, circulation and colour (40). This scoring system 
conveys information about physiologic stability and its return to preoperative levels or 
baseline. It was and still is used primarily as a guide for early recovery and transfer from 
PACU to the in-patient ward. It does not provide information about late recovery. 
Late recovery assessment conveys information about residual drug effect on 
cognitive function and assesses ability to return to real life tasks. Subjective assessment 
of late recovery maybe made by the patient or the PACU nursing staff but objective 
assessment using neuropsychological testing may be more sensitive to residual anesthetic 
effects on cognitive function (these residual effects may actually reduce patients' insight 
into their own mental impairment)(39). 
Neuropsychological testing ( 41) may serve as surrogate markers to assess the 
recovery of these functions. Neuropsychological tests are objective assessments made on 
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various aspects of psychomotor function using "idealised tasks" such as "reaction time" 
(as opposed to "real tasks" such as "driving an automobile"). Neuropsychological tests 
have been adapted or modified from the psychology literature where they are used to test 
intelligence. The results are then interpreted using psychological models of cognitive I 
psychomotor function (39). 
Cognition or psychomotor function is multidimensional encompassing areas such 
as sensory input processing, motor function, central processing, vigilance, and memory. 
Different sub-tests measure different aspects of psychomotor function. Performance on 
neuropsychological tests and exact clinical significance and correlation with decision 
making or "street readiness" is still ambiguous. Generalisation about street fitness and 
return to baseline measure must be made with caution (39,64). It may not be possible to 
measure or assess complex human behaviour especially around "decision making 
processes" but these idealised tasks are likely the best assessment tool or surrogate 
makers of it. 
Discharge Assessment 
Discharge from P ACU may be to the inpatient ward or as in ambulatory surgery 
to home. Assessment for discharge from P ACU occurs somewhere between intermediate 
and late recovery. Criteria used to transfer a patient to the ward cannot be used alone in 
ambulatory patients to determine "home readiness" (42). Ambulatory patients who are 
"home ready" are clinically stable, have recovery ofbasic cognitive function and have 
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regained the ability to walk, void and maintain adequate oral intake and pain control. 
This is a much higher standard compared to inpatient discharge. 
"Street readiness" after anesthesia likely includes the ability to return to complex 
tasks such as crossing a street, using public transportation unaccompanied or driving. It 
is difficult to determine exactly when complete recovery of these complex cognitive 
functions occurs. The ability to sign legal documents according to Canadian 
Anesthesiologist's Society guidelines2 is no earlier than 24 hours post anesthesia 
Neuropsychological Tests of Cognitive Recovery 
When considering which test to use to measure cognitive recovery, several factors 
need to be assessed. Ideally in clinical practice these tests must be quick and simple to 
administer, have no learning effect, can be used by an unskilled operator and require 
inexpensive equipment. The tests should be validated in the post general anesthetic 
population. Late recovery or assessment of cognitive recovery utilising 
neuropsychological testing is used in the anesthesia research I literature. These 
neuropsychological tests maybe complex, time consuming and may require standardised 
administration. These tests and therefore assessment of late recovery are not routinely 
used in clinical practice. 
2 Guidelines to the Practice of Anesthesia as recommended by the Canadian Anesthesiologist's Society. 
Toronto Canada 2003 
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Benzodiazepines and Cognitive Function 
Benzodiazepines are classed as sedative-hypnotics (oral sleeping pills I 
anxiolytics). They are true amnesties in that they can produce amnesia without sedation. 
Most anesthetic agents may produce amnesia only if they are sufficiently sedating. 
Benzodiazepines have been documented to have impairment or "hangover" effects on 
cognitive function extending after the sedative effect has gone (43). These undesirable 
effects impair learning, memory and psychomotor functions (43,44). This can be more 
pronounced in geriatric patients ( 45). As earlier indicated midazolam for general 
anesthesia induction has been shown to prolong standard recovery assessments. 
Midazolam as a preoperative sedative have conflicting reports on its effect on recovery 
( 46,4 7). Concerns about potency and the residual effects of intravenous midazolam 
increased in 1988 after 57 reports during a 2 year period to the FDA involving 30 deaths 
with midazolam conscious sedation ( 48). This correlated clinically to what other local 
health care providers (personal communication) were observing when midazolam was 
used for procedural conscious sedation. The patients look awake and respond 
appropriately during post procedure conversation. They appeared suitable to discharge 
home, however on follow up patients would often have no recollection of the 
conversation. The patients did not recall post procedural instruction or restrictions and/or 
test results. The potential and duration for post procedure respiratory depression did have 
catastrophic consequences. The duration of post procedure amnesia was uncertain and a 
second area of risk in ambulatory patients. Retrograde and anterograde amnesia after 
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benzodiazepines administration may be desired during and before general anesthesia, 
anterograde amnesia certainly is undesirable after general anesthesia is complete. This is 
particularly true in the ambulatory anesthesia patients who are discharged home, appear 
to be back to preoperative function but in actual fact may have no recollection of the first 
few hours after their discharge. 
Midazolam Coinduction and Recovery 
Given this background information i.e. effects of benzodiazepines on cognition, 
need for fast recovery and early discharge, the effect on recovery of a coinduction 
technique within the context of ambulatory anesthesia was questioned. Was there need 
for concern using a very low dose benzodiazepine -one-tenth the ED50 for induction or 
one-fifth to one half conscious sedation doses? It was unclear as to what would happen 
to the recovery characteristics after a midazolam coinduction technique. The risk I 
benefits of adding a low dose benzodiazepine during a coinduction technique was 
questioned in many operating room lounges and anesthesia society meetings. Would it 
indeed speed up time to eye opening and possible time to discharge due to lower over all 
drug administration or cognitively impair patients due to the benzodiazepine effect 
possibly making discharge especially early discharge unsafe? Could the addition of a 
benzodiazepine with documented anterograde amnesia be protective against intra-
operative recall? The answers to these questions were not readily apparent. 
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LITERATURE REVIEW 
A primary literature review was conducted initially in 1996 using the National 
Library of Medicine MEDLINE (Silver Platter CD-ROM version initially and then 
WinSpirs). In early 1997 the search was updated and conducted via Grateful Med 
(Internet version). Initially we were interested in finding trials similar to our own 
practice using midazolam propofol coinduction and cognitive recovery characteristics. 
The database back to 1966 was searched using midazolam, coinduction, cognition, 
neuropsychological recovery, discharge, and general anesthesia (see Appendix A). As 
this was a relatively new technique these searches revealed very little published data on 
midazolam coinduction and even less on recovery characteristics. We broadened our 
search to retrieve general studies of coinduction using alternative anesthetic agents, drug 
synergy including midazolam, and any reports on midazolam co induction techniques. 
These searches revealed numerous articles documenting drug synergy utilising various 
agents including midazolam, midazolam as an intravenous induction agent, but only three 
articles noting recovery characteristics after midazolam coinduced general anesthesia 
(328,29,49). 
These consisted of two abstracts and one publication, which were retrieved. A 
secondary search of any applicable references within these articles was hand reviewed 
and retrieved. The secondary search also included a Science Citation Index search. This 
was conducted to find any further publications that had subsequently cited these articles 
and had not initially been found. If necessary, personal communication with the authors 
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was attempted for clarification about methodology or if unanswered questions remained. 
This yielded the full text article of one of one the initial abstracts retrieved. 
The three articles that appeared to be applicable are as follows. Delucia et al (27) 
published an abstract in 1992 titled "Effect of Midazolam on Induction and Recovery 
Characteristics of Propofol" describing results of a randomised control trial of 7 5 patients 
undergoing brief general anesthesia using placebo, low or high dose midazolam along 
with propofol for induction. This study was designed to evaluate perioperative effects of 
intravenous midazolam when administered as an adjuvant to propofol for coinduction of 
outpatient anesthesia. The assessment of recovery found a statistically significant 
prolongation of awakening and time to extubation and time to orientation in the high dose 
midazolam group but not in the low dose midazolam group. Neuropsychological tests or 
further cognitive assessments were not completed. Despite contacting the research 
supervisor (co-author) no subsequent publication of these data in full article format could 
be found and appears was not completed. 
Elwood et al (28) published in 1995 a randomised control trial of 64 patients 
undergoing short elective procedures with general anesthesia. Patients were randomised 
to receive placebo, low or high dose midazolam along with propofol for coinduction. 
Time to eye opening and time to discharge were used to assess recovery characteristics. 
A statistically significant delay in time to eye opening was found, with no difference in 
time to discharge (Power 80% to find 39-min. delay). No neuropsychological 
assessments of cognitive recovery were done. 
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Work by Miller et al ( 49) in 1995 abstract and the full article published 1996 
evaluated the synergistic drug effects of midazolam on propofol requirements and 
recovery quality of this combination used during a total intravenous anesthetic (TIVA) 
technique. The primary outcome of this study was the effect of graded doses of 
midazolam on propofol induction requirements and on maintenance infusion rates. The 
effect on recovery times including assessment of cognitive function and patient 
satisfaction were secondary outcomes. Recovery was assessed by time to awakening, 
time to discharge and score on "psychometric" (neuropsychological) testing (Trieger Dot 
Test). 
A TIV A technique does not use inhalation I volatile vapour anesthetic for 
anesthesia maintenance. TIV A uses an intravenous infusion of an anesthetic agent using 
volumetric infusion pump for maintenance of anesthesia. TIV A general anesthesia is not 
the standard technique for general anesthesia administration. Midazolam, as expected 
with drug synergy, in this study reduced the induction requirements but surprisingly not 
the maintenance requirements ofpropofol for TIVA (49,50). Compared to standard 
inhalation anesthesia for maintenance, there is a much larger total drug dosage of 
propofol used for the TIV A anesthetic. These two anesthetic techniques may differ in 
terms of recovery qualities and benzodiazepine effects of them. It may not be valid to 
extrapolate these results from a study of total intravenous anesthesia to a setting with 
coinduced inhalation general anesthesia. 
A sample size of 100 subjects was used but details of sample size estimation were 
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not included. Ninety of 100 ambulatory patients undergoing short surgical procedures 
were randomised into 4 groups to receive placebo or one of three midazolam dosages. 
This study was discontinued before the complete sample size was attained, as an 
unexpected high incidence of intraoperative awareness was encountered with the TIV A 
technique. Despite this data analysis was completed and no statistically significant 
differences were found in either of the recovery assessments including the TDT over time 
for the four treatment groups (Kruskal-Wallis a=O.OS). 
This study, which was halted because of an unusually high incidence (6.7%) of 
intraoperative awareness which was felt to be as a result of inadequate anesthesia with the 
TIV A technique (spontaneous reporting of awareness is reported Lui (51) to be 0.1 -
0.2% of all general anesthetics). It is of interest that the 4 of the six subjects who 
experienced intraoperative recall were in the placebo group, one of the six in the low dose 
midazolam group. The rate of intraoperative recall between the groups did reach 
statistical significance. It is noted that the midazolam group of patients while requiring 
less induction drug received similar propofol maintenance infusion rates as the placebo 
group. The authors postulated that midazolam from anterograde amnesia may afford a 
protective effect on intraoperative recall. The authors suggested that midazolam should 
be added to TIV A techniques. 
The data from all these studies provided some evidence that midazolam in high 
dose coinduction techniques but not low dose techniques may delay early markers of 
recovery such as time to eye opening, time to awakening and extubation. This however 
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did not delay discharge time. The studies using low dose midazolam had equivocal 
effects on either early recovery characteristics but again did not delay discharge. 
It was apparent that insufficient evidence existed to determine if midazolam 
coinduction impaired neuropsychological markers of cognitive recovery post general 
anesthesia. As previously stated, recovery of cognitive function is subtle to assess post 
general anesthesia and likely is not assessed using routine markers of physiological 
recovery. While there are some publications that attempt to address the effect of 
midazolam coinduction on cognitive recovery, we felt that these assessments were not 
valid measures of complex cognitive function. We wished to have a more precise 
validated assessment of the cognition, which may or may not be more relevant to clinical 
recovery of higher cognitive function or if possible assess "street readiness" after general 
anesthesia. 
Hence, the rationale leading to a well designed, randomised control trial to 
determine whether there is a significant treatment effect of midazolam coinduction on 
cognitive function as measured by neuropsychological tests. Secondary outcomes were 
to look at various intraoperative parameters such as induction characteristics i.e. 
reliability, hemodynamic stability, adverse events and overall induction agent drug cost. 
Postoperative variables to be assessed included narcotic and anti-emetic requirements, 
Aldrete score, time to discharge and intraoperative recall. 
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STUDY OBJECTIVE 
The goal of this study is to determine whether midazolam given in low doses 
during coinduced general anesthesia adversely affects or slows cognitive recovery by 
comparison of those subjects who receive this benzodiazepine as part of the general 
anesthetic induction to those who do not. 
RESEARCH QUESTION 
In ambulatory gynaecologic patients undergoing elective laparoscopic procedures 
of short duration (30 to 90 minutes), is there a clinically important difference in cognitive 
function on neuropsychological testing during recovery as measured by the Digit Symbol 
Substitution Test in patients receiving midazolam coinduced general anesthesia compared 
to standard propofol induction of general anesthesia? 
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RESEARCH DESIGN 
CHAPTER2 
Research Design and Methods 
This clinical trial was a prospective, randomised, double blinded study. 
Blinding 
Patients enrolled in the study were not aware to which treatment group they were 
randomised and which drugs they received. The investigator performing the outcome 
assessments was not aware of the patients' treatment group. It is hoped that bias on the 
part of the investigator or the patient will be minimised by this endpoint blinding. 
The attending anesthesiologist administering the general anesthetic was not 
blinded. After randomization, the anesthesiologist was given the treatment assignment 
in an envelope. The envelope contained a card noting the study number and treatment 
assignment. The envelope on the exterior indicated drug dosages for both study groups 
based upon the patient's weight. Only the study number was documented on the 
anesthetic record. The total drug dosages that were administered was recorded on the 
card and placed inside the envelope. The card was sealed in the envelope and attached to 
the to the consent form and anesthetic record on the patients chart. This allowed safety in 
administration of study drugs, blinding of the anesthetic record as well as immediate 
ability to unblind the study drugs if an adverse reaction occurred. This is done without 
compromise to the study integrity, as the attending anesthesiologist did not complete any 
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of the outcome assessments. 
The attending anesthesiologist and operating room nurses were reminded prior to 
start of each study case that the drugs administered were not to be revealed to either the 
patient, PACU staff or the outcome assessor. The induction drugs were drawn up 
between surgical cases (only cleaning staffs were present). The surgical team was 
blinded, as they were not in the operating room during anesthetic induction. It is possible 
that nursing I scrub staff who were present during administration of induction drugs may 
have been able to identify the drugs administered and therefore aware of group 
assignment. 
The outcome assessor and P ACU staff only had access to the patient's blinded 
anesthetic record. Subsequent to the outcome assessment and grading, the group 
assignment was then unblinded by opening the sealed envelope. The group assignment 
and drug dosages administered were then noted on the data collection record. 
Randomization 
Subjects were randomised by blocked, stratified randomization to either 
Group A propofol 2mg /kg or 
Group B midazolam 0.02mg/kg: propofollmg/kg. 
using a sealed envelope system. 
Variable blocking of randomization was utilized. The size of the block was 
determined empirically as an even number chosen from 6 to 20 to a total of 88 subjects. 
Stratification for age was carried out for each randomization group. The 
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definition of elderly, while arbitrary is usually age greater the 65 years (52). Healthy 
elderly patients exhibit normal physiologic change associated with ageing. These 
changes include physiologic reduction in organ function and altered redistribution 
kinetics (1,52,53). This, in addition to chronic disease co-morbidity and poly-pharmacy, 
influences the pharmacokinetic and pharmacodynamic properties of most therapeutic 
agents. 
Elderly patients may require weeks to months to recover full preoperative mental 
status (54). In one study, 13% of elderly patients had some form of long term memory 
loss or "serious mental deterioration" after surgery (55). Age therefore is an important 
prognostic factor in cognitive recovery from general anesthesia. Increasing age has been 
shown to be a factor in prolonged duration of effects of benzodiazepines on cognitive 
function (52). The Wechsler Adult Intelligence Scale (WAIS) (56) manual has 
normalised sub-test scores for age. The norms table is subdivided into groups of 55-64 
and 65-69 years of age. For these reasons age was stratified into two groups (younger 
than 65 years and 65 years and older) prior to group randomization. 
Randomization Envelope Assembly 
Randomization envelopes were assembled by a disinterested third party 
(departmental secretary). She would determine block size, then assign half of the block 
size to Group A -standard treatment and half to Group B -the intervention group on an 
index card. The cards were then shuffled and placed within opaque envelopes. The 
envelopes were sealed and shuffled a second time. The randomization number was then 
27 
written on the envelope exterior in order from 1 to 88. Randomization envelopes were 
placed sequentially in a box in the research office within the Department of Anesthesia. 
Randomization envelops where then removed from the box in correct numeric order. 
Once removed from the box, the randomization envelope, along with the patient data 
collection record and consent form, was placed on the patient's chart to accompany the 
patient into the operating room. 
Allocation of treatment was therefore due to chance with important characteristics 
such as weight, ASA class, or length of surgery also being distributed equally by chance. 
Randomization also tends to equally distribute unrecognized confounding factors in the 
long run. Despite proper randomization, chance may still lead to imbalance in a small 
trial such as this. Variable blocking limited the possibility of guessing group 
randomization and assured equal distribution of the groups throughout the study duration. 
STUDY POPULATION 
The following inclusion and exclusion criteria were used when subject selection was 
conducted. 
Inclusion Criteria 
• American Society of Anesthesiologists (ASA) class 1-3 
• Age> 18 years 
• Duration of procedure 30-90 minutes 
• Gynaecological ambulatory population 
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• Unpremedicated 
The ASA classification describes a patients' physical status or health. Classes 1 to 3 
were as chosen, which includes a range from healthy patients to those with severe, but 
not incapacitating systemic illness. We desired healthy patients who would be eligible 
for ambulatory procedures, yet did not want to exclude those with moderate I severe 
systemic illness who were deemed well enough for ambulatory procedures. The age of 
18 years or greater was chosen as this was the age of ability to give consent. We chose 
Gynaecology patient population, as this group of patients was most readily available for 
study recruitment within my anesthesia practice. We chose not to have patients pre-
medicated, as we did not want to confound our results by the use of preoperative 
benzodiazepines. Preoperative use of a benzodiazepine would also likely inhibit the use 
of intraoperative midazolam coinduction due to the perception of excessive postoperative 
sedation if two doses of benzodiazepines were given in combination. 
Exclusion Criteria 
• Pregnancy 
• Previous sensitivity to any of the agents used including: 
• Propofol - constituents 
• Midazolam 
• Psychoactive/narcotic medications during prior 1 week i.e. 
• Narcotics 
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• Benzodiazepines 
• Barbiturates 
• Anti- epileptic medications 
• Anti- psychotic medications 
• Not able I willing to provide informed consent 
• Pre-existing cognitive deficits 
• Alzheimer's 
• Dementia 
• Developmental Delay 
The use of propofol and midazolam is still not approved within the pregnant 
population. The remainder of the exclusion criteria was chosen again to prevent 
confounding ofthe study outcome assessments. Preoperative use of psychoactive 
medications may have influenced the assessment of cognitive function postoperatively, as 
might the existence of a pre-existing cognitive deficit. The DSST and the TDT scores 
were assessed using "norms" from varying age groups so it was therefore felt to be valid 
to exclude these groups. 
ETHICAL CONSIDERATIONS 
Application and full approval was obtained in April 1996 from the Human 
Investigation Committee (Appendix B) Memorial University of Newfoundland, Office of 
Research and Graduate Studies to be conducted at the Health Care Corporation (three 
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Hospital Sites). The study did not get conducted until a combined Clinical I Research 
Fellowship in Obstetric Anesthesia was secured in 1999 through an IWK Board of 
Directors Fellowship grant. 
Application to the IWK-Grace Health Centre Research Ethics Committee was 
completed July 1999 and full approval was granted September 1999. This study followed 
MRC 1987 "Guidelines to Research Involving Human Subjects"3. 
Subjects were initially identified from published operating room lists and were 
deemed eligible based upon of type and duration of booked surgical procedure. Under 
the MRC 1987 guidelines it was acceptable for patients to be approached by non-primary 
caregivers to enrol in research trials. The principal investigator recruited patients the day 
of surgery, usually two hours before the scheduled operation. 
Patients were given a copy of the consent form (Appendix C) and given time to 
consider if they would like to participate. The decision to enrol was purely voluntary 
with protection of patient rights. The patients understood that there was no compensation 
for study enrolment. Withdrawal from the study was possible and could be done at any 
time. Patients were to understand that this would not affect their subsequent anesthetic 
care. Consent was then obtained by one of the recruiters. 
All patient records and data forms were kept strictly confidential. Subject names 
were not used on the data collection records and were only identified by randomization 
number. The investigator had a logbook in which the patient name I health record 
number recorded along with their randomization number. This was kept in a locked 
3 Now replaced with Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans 1999 
31 
drawer in the Department of Anesthesia research office. Patients were offered access to 
the results of the study if they desired and the researcher was available at all times during 
the study to answer questions should they have arisen. 
Recruitment of patients 
Patients were recruited March to August 2000 from the gynaecologic ambulatory 
patient populations scheduled to under go elective laparoscopic procedures. Attending 
anaesthesiologists and the attending gynaecologists (Appendix E) had agreed to let the 
investigator approach suitable patients identified from published operating room lists. 
Contact with the patient was made through the Day Surgery I Same Day Admission 
waiting area, usually two hours before the scheduled procedure. If patients were 
interested and permission was granted, assessment of inclusion/exclusion criteria was 
done by the investigator. If these criteria were met, patients were invited to participate in 
the clinical trial with full explanation of the study protocol. Foreseeable risks and 
benefits including possible delay or improved time to discharge, possible cognitive 
impairment I improvement was explained. 
OUTCOME MEASURES 
Cognitive function is complex involving numerous aspects of cerebral function; 
i.e. sensory input processing, motor function, central processing, vigilance, memory, etc. 
There are a huge number of these tests that have been used to assess recovery from 
anesthesia. Individual neuropsychological tests generally assess one part of the complex 
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interaction of cognitive function. Ideally a complete set of tests would be compiled to 
assess all aspects of mental activity to give a global assessment of function. In practice, 
we limit tests we use as anesthesia affects all aspects of cognitive activity. Otherwise this 
set would be excessive. A minimum complete set of psychomotor tests post general 
anesthesia would assess perception, co-ordination and central activity (39). When using 
neuropsychological tests precautions must be taken to maintain construct validity. 
Individuals vary considerably in their baseline abilities, practice effects must be 
considered, and sophisticated tests may actually create interest therefore increase arousal 
and influence test results (39,66). 
A minimum complete set of psychomotor tests post general anesthesia was 
constructed. It consisted of two objective measures of neuropsychological recovery the 
Digit Symbol Substitution Test® (DSST) and the Treiger Dot Test (TDT). It also 
contained 5 Visual Analogue Scales as a subjective measure. These tests were conducted 
preoperatively and postoperatively every thirty minutes once an Aldrete Score of 7 or 
greater was attained. Copies of these tests are included as Appendix D. 
The DSST is a subset of the Wechsler Adult Intelligence Scale (56) battery of 
neuropsychological tests. These tests are used by psychologist to assess adult intellect I 
cognitive function. In the DDST sub-test the subject is presented numbers 0-9 to 
matching nonsense symbols. The task is to copy the appropriate numbers into boxes 
labelled randomly by the symbols. The score is the number of items substituted correctly 
in 90 seconds. If the test is repeated, a new set of numbers/symbols must be used to 
prevent learning. The Psychological Corporation, Harcourt Canada (the copyright owners 
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of the Wechsler Adult Intelligence Scale) was contacted and provided with permission 
four equivalent versions (by rearrangement of symbol I number relationships in a random 
fashion) of this test. Instructions were given according to the W AIS-r4 administration 
and scoring manual. The DSST involves sensory input, central processing, motor co-
ordination and ability to perform. It is a sensitive test to the effects of many anesthetic 
drugs including benzodiazepines on perceptual processing and coding I memory skills 
(39,43,48,57-59). 
The Trieger Dot Test (TDT) was first described in 1969 and is a modified version 
of Design 4 of the Bender-Gestalt Test (60). Trieger et al modified the administration 
and scoring method to specifically assess recovery from anesthesia. The TDT requires 
the subject to draw a figure by joining 42 dots placed at 12-13 mm intervals. The number 
of dots missed, time taken to complete and error of magnitude (cumulative distance of 
miss in mm) from base line was originally described. Subsequent modifications have 
added a "timed" component and I or omitted the error of magnitude (35,49,61). This 
study measured the number of dots missed in 30 seconds. The TDT measures sensory 
processing I perceptual ability as subjects need to see the figure in the dots and motor co-
ordination is needed not to miss the dots. 
Subjective assessment of cognitive function was included in the battery of 
neuropsychological testing (Appendix D). Subjective measures of neuropsychological 
recovery consisted of five Visual Analogue Scales that were again scored every thirty 
minutes concurrently with the objective measures. The 5 different Visual Analogue 
4 This version has now been replaced with the W AI S-Ill 
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Scales (VAS) included as an assessment of patient perception and insight into their 
cognitive function (62). The five VAS 100mm scales asked patients to rate their feelings 
of drowsiness, confusion, co-ordination, anxiety, and sedation. As a measure of internal 
reliability of VAS scores, the assessment of level of consciousness was asked twice using 
two different descriptors i.e. feelings of drowsiness (alert I extremely tired) and feelings 
of sedation (wide-awake I almost asleep). 
Validation of Neuropsychological Tests in Anesthesia 
Bond and Lader (44) in 1972 found the DSST to be a sensitive measure of 
residual effects of benzodiazepines on human performance. These residual effects were 
observed to occur in a dose related manner. Chernik et al in 1982 (43) reviewed 
published studies to assess the effects of sedative-hypnotic drugs on human performance. 
This group made several conclusions after reviewing 52 studies assessing human 
performance on 15 "tasks" or neuropsychological tests. They concluded that different 
psychomotor performance tests are differentially sensitive to the effects of sedative-
hypnotics and that there was consistent dose differences i.e. the higher the dose, the 
higher the performance decrement. They concluded long-acting drugs had more 
performance decrement but that the long elimination half-life could not be reliably used 
to predict performance effect over time. They also concluded that of the 15 tests 
assessed, the DSST was one of the four most sensitive tasks for assessing benzodiazepine 
effect on human performance. Subsequent studies have used the DSST as an objective 
assessment of psychomotor function after midazolam administration (57,59,61,63). 
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The TDT was validated in 1969 as a test of recovery from anesthesia. The test 
performance (improvement over time towards base line) was directly and significantly 
related to recovery as defined as period from awakening to discharge time (60). 
Subsequent reliability and validity has been shown (64) with studies were published for 
performance effects after narcotic, general anesthesia inhalation agents and 
benzodiazepines (including midazolam) (33,35,46,49,61). 
The VAS scores were included to assess cognitive recovery for several reasons. 
Firstly, they are validated assessment tools of cognitive function in both benzodiazepine 
and general anesthesia assessment (48,57,61,67). Secondly they were used to correlate 
patient perception I insight of cognitive function with the objective measures. 
Primary outcome 
The primary outcome measure was the difference in DSST score as assessed at 
the 60 minute postoperative assessment adjusted for baseline preoperative score between 
the midazolam coinduction group and the standard propofol induction group. 
The clinically significant change in DSST score to determine alteration in 
cognitive function was determined by looking at DSST scores in previously published 
work by Chemik and associates (57). This study used several assessment scales to assess 
alertness in subjects administered midazolam. Patients assessed at 60 minutes post 
midazolam administration "lightly sedated" had a mean score of26.7, heavily sedated 
had a score of 13.7 and not sedated (placebo) 4 7.3. This yielded a clinically significant 
score of 13. The decision to not use the placebo baseline score of 4 7.3 was justified as it 
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was unlikely with residual effects of the general anesthetic agents I P ACU analgesia 
would likely prevent attaining scores as low as placebo. Supporting this assumption was a 
study of general anesthesia using midazolam as an induction agent reported a DSST score 
of36 at 60 minutes postoperative (61). 
The sixty-minute time period was felt to the most clinically relevant assessment. 
This is the earliest time period in our institute when a patient would first be considered 
for discharge. It therefore is important to determine what the status of cognitive function 
recovery at that time would be. After this time period it is likely that the majority of 
patients would be discharged and attrition of subject numbers would likely prevent 
conclusions from data analysis. This is also the time period taken for our base-line 
estimate ofDSST scores for heavy and light sedation. 
Data Collection and Secondary Outcomes 
Data were also collected on various intra-operative variables (table #2.1) and 
postoperative variables (table # 2.2) to assess other possible clinically significant 
outcomes that may differ between the two anesthetic techniques. This data was collected 
in the preoperative and postoperative periods. The intraoperative data and postoperative 
data were collected in the P ACU from the perioperative record, the anesthetic record and 
the P ACU record. The secondary outcomes included the Trieger Dot Test and the Visual 
Analogue Scale scores. The Trieger Dot Test and Visual Analogue Scale scores were 
included as part of the battery of objective measures of neuropsychological recovery. As 
previously discussed these were felt to be important in the overall assessment of the many 
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aspects of cognitive function. The other secondary outcomes included assessing effects 
of midazolam on intraoperative hemodynamics, total fentanyl (intraoperative narcotic 
dose), failure of induction rates (reliability), and adverse intraoperative events. During 
the post anesthesia period secondary outcomes included total morphine dose 
(postoperative narcotic use), length ofPACU stay, Aldrete Scores and ondansetron 
rescue use (postoperative nausea I vomiting rates). 
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Table#2.1 Summary of variables for which data was collected during the 
intraoperative study period. 
Intraoperative Variables 
Procedure type 
Start time 
Finish time 
Duration 
Preoperative vitals 
Intraoperative vitals every 15 minutes 
Failure of induction 
Propofol dose (mg/kg) 
Fentanyl dose (mg/kg) 
Midazolam dose (mg/kg) 
Muscle Relaxant used 
Anti-emetic prophylaxis 
NSAIDS used 
Adverse events 
Table#2.2 Summary of variables for which data was collected during the 
postoperative study period. 
Postoperative Variables 
Aldrete Score 
P ACU narcotic requirements 
(morphine mg/kg) 
P ACU anti-emetic rescue 
Discharge time 
P ACU length of stay 
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The secondary outcomes and data were collected to enable a more complete 
assessment of the impact of midazolam co induction. The secondary outcome data may 
reveal unanticipated effects of midazolam co induction upon other important anesthetic 
qualities. These include assessments of quality of induction, change in the incidence of 
postoperative nausea or analgesic requirements. The analysis of the TDT scores and 
VAS scores will hopefully support the findings on the DSST and allow a comprehensive 
assessment of cognitive function. Analyses of secondary outcomes may also allow 
hypothesis generation for questions that need to be further assessed. 
SAMPLE SIZE CALCULATION 
Formal sample size estimation was conduced a priori. This was based on the 
primary outcome variable Digit Symbol Substitution Test Score (56). The standard 
deviation and mean was obtained from previous work (57). The clinically significant 
change of 13 was arbitrarily determined by the difference in scores on DSST between 
light and heavy sedation after benzodiazepine sedation (57). Number that was calculated 
per group 35 and adjusted for dropouts is 43. 
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Sample Size Formula- Per group based on Independent Group Means5 
n I group= 2 [Za + ZP] cr I ~]2 
where by Za = 1.96 
zp = o.84 
(J = 20 
~ = 26.78-13.7 
=13.0 
n I group= 2 [Za + Zp] cr I ~]2 
= 2 [1.96 +0.84] X 20 I 13.0]2 
=2 [2.8 X 1.5]2 
= 35 
Anticipated Dropouts I Non-compliance (R) 
R = 1 0% (estimated drop out rate) 
n I group= n x 1 I (l-R)2 
= n x 1 I (1 x 0.10i 
= n x 1 I (0.9i 
= 35 X 1.23 
=43 
a = 0.05 two tailed test with 
equal allocation of Type 1 error in 
each tail (0.025) 
p = 0.20 
o = DSST standard deviation 
J..L1= light sedation mean DSST 
score 
J..L2= heavy sedation mean DSST 
score 
(Previously published work5) 
A = J..Lt - J..L2 difference clinically 
significant difference between the 
group DSST means 
Number that was calculated per group 35 and adjusted for dropouts is 43. 
5 Chemik D.A., Gillings D., et al Validity and Reliability of the Observer's Assessment of 
Alertness/Sedation Scale: Study with Intravenous Midazolam Journal of Clinical Psychopharmaclogy 
1990;10:4 244-251 
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THERAPEUTIC INTERVENTION 
Subjects were randomised to either 
Group A propofol2mg /kg (control group) or 
Group B midazolam 0.02mg/kg: propofollmg/kg (intervention group). 
Clinical Protocol 
All patients entering into the study received a standardised general anesthetic. 
The drugs, sequence of administration as well as the intubation and extubation of the 
trachea was to be essentially the same for all study subjects. This was to minimise any 
confounding effects that other concomitantly administered drugs I anesthetic techniques 
could have on the outcome assessments. 
After placement of appropriate monitors, insertion of a peripheral intravenous 
catheter with good flow of physiologic saline or lactated Ringer's solution, induction of 
anesthesia was commenced. During preoxygenation both groups received fentanyl 
2mcg/kg. If assigned to treatment Group B then midazolam 0.02mglkg was also 
administered at this time. These drugs were flushed through the intravenous line with 
physiologic saline or lactated Ringer's solution for 2 minutes. After the two minutes had 
elapsed, the appropriate dosage of propofol was administered. Assessment of hypnosis 
was carried out after the completion of injection ofpropofol (approximately 3 minutes 
after administration of fentanyl and/or midazolam). Hypnosis was assessed by failure to 
respond to the verbal command "open your eyes", or loss of eyelash reflex. Failure of 
induction was treated with further propofol 0.5mg/kg and this was noted in the outcome 
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assessment. 
Once the patient was observed to be apneic i.e. no spontaneous respiration for 15 
seconds the anesthesiologist commenced mask and ventilation and intubated the trachea. 
Endotracheal intubation was facilitated by administration of succinylcholine (1.5 mg/kg) 
and I or rocuronium (0.6 mglkg). Anesthesia was continued as appropriate for the 
surgical procedure. Anesthetic maintenance drugs consisted of 50% nitrous oxide with 
50% oxygen mixture together with the volatile inhalation anesthetic sevoflurane 
(Sevorane AF™). Initial over pressure technique was permitted to attain an end tidal 
concentration of sevoflurane between 1-3%. Non-steriodal anti-inflammatory agents 
(ketorolac (Toradol®) or naprosyn (Anaprox®)) etc) were to be given unless 
contraindicated. Anti-emetic agents (ondansetron (Zofran®)) were permitted as 
clinically indicated. A standardised protocol specified intervention to anticipated 
common intraoperative events i.e. hemodynamic change, light anesthesia (need for 
additional inhalation anesthesia I narcotic) or additional muscle relaxant was provided. 
This was provided to maintain equivalence in anesthetic technique in all aspects except 
the administration of midazolam. The outline of the standardised anesthetic and 
interventions are detailed in Appendix F. 
Required hemodynamic measurements included at least one baseline pre-
anesthetic heart rate, blood pressure, and Sp02 measurements. Subsequent 
measurements were carried out 1-minute post intubation and at 15-minute intervals 
during the remainder of anesthetic maintenance6. Adverse events such as hemodynamic 
6 CAS Guidelines to the Practice of Anesthesia require vitals every 5 minutes on the anesthetic record. 
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compromise requiring treatment, bronchospasm, arrhythmia etc was recorded and 
included in data analysis. 
Reversal of anesthesia was to be carried out in the usual manner using 
neostigmine 50 meg/kg with glycopyrrolate O.Olmcg/kg as necessary. End tidal 
concentration of sevoflurane was to be less than 0.40% prior to extubation. Extubation 
was to be carried out as clinically appropriate and patients were to be transferred to the 
Post Anesthesia Care Unit (PACU) in the usual manner. 
PACU assessments and administration of medications were completed as per unit 
protocol. This included hemodynamic and respiratory monitoring and assignment of 
Aldrete post anesthetic recovery score (36). Analgesia and anti-emetic medications to be 
administered as clinically indicated by assessment of pain sedation and nausea included: 
Analgesia - morphine 2 mg -4mg IV PRN 
Nausea- ondansetron (Zofran®) 4mg IV PRN 
DATA RECORDS 
Data and outcome assessments were collected on data collection records and 
scored by either the principal investigator or a fourth year medical student. Prior to data 
collection, assessors reviewed the Treiger Dot Test and the W AIS sub-test DSST 
administration, according to the published W AIS-r administration manual and previously 
published techniques. A research assistant, using the Statistical Package for Social 
Sciences (SPSS-) manually entered into a computer file from data collected on Data 
Collection Records (DCR) (Appendix G). Accuracy of manual data entry was checked 
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using the individual DCR and raw data print out sheets by the principal investigator. 
Outlying or missing data was also rechecked to ensure for accuracy of data entry. 
DATA ANALYSIS 
The statistical approach to this clinical trial is based upon the null hypothesis and 
logic of proof such that the study results either allow the investigation to accept or reject 
the null hypothesis. 
Ho: f.tl = f.t2 
Ha: f.tl f. f.t2 
The null hypothesis tested in this clinical trial "There is no clinically significant 
difference between 60 minute DSST scores in patients treated with midazolam coinduced 
general anesthesia compared to standard propofol induced general anesthesia". 
The significant p value, or the probability of making a Type I error, was 
designated at 0.05. The probability of making a Type II error has been set at 0.20. This 
gives a slightly higher risk at accepting an incorrect null hypothesis. 
Descriptive statistics were used to describe patient demographics. The baseline 
patient demographic variables will not be statistically compared as suggested by Altman 
(73). If appropriate randomization techniques have been utilised any differences in 
baseline characteristics between the treatment and control groups should occur by chance. 
This was a randomised study and consequently, by definition, any differences between 
the treatment and control groups are by chance. 
Frequency counts; percentages, means and standard deviations were calculated for 
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various intraoperative and postoperative variables. Analysis of Covariance was used to 
analyse neuropsychological test results. Treatment effect with respect to the primary 
outcome variable DSST Score was first compared using Student's t-Test for parametric 
data and independent group means. Analysis of covariance for repeated measures was 
also applied, with baseline values serving as a covariate. This was to adjust for any 
observed inter-group difference at baseline in the outcome measures. A linear regression 
analysis of the data was also planned (time permitting) to determine ifthere are any 
variables or patient characteristics that predicted prolonged Post Anesthesia Care Unit 
stay. 
The data from the secondary outcomes was analysed to support the findings of the 
primary outcome. Secondary outcomes, as previously mentioned, should be treated 
primarily as hypothesis generating not hypothesis testing. Analysis included both 
Student's t-Test and Analysis of Covariance where appropriate. 
BUDGET 
A copy of the trial budget is included as Appendix H 
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CHAPTER3 
Results 
SUBJECT RECRUITMENT AND RETENTION 
This study was pilot tested from February 8-17, 2000 on 4 subjects. The complete 
processes of screening, enrolment, consent; administration of the standardised anesthetic 
and outcome assessments was tested. Data collection records, including 
neuropsychological assessments, were assessed for ease of patient understanding and 
ease of data collection. There were no major problems identified and the pilot data were 
not included in the study results. Subject recruitment commenced March 27, 2000 and 
was completed August 21, 2000. During this time, study patients were recruited on 
average 2 days per week dependant upon the investigator availability and suitability of 
scheduled operating room cases I list. 
Formal data collection was limited to patients enrolled in the study. Data were 
not collected on screened but non-enrolled patients. However, overall patient acceptance 
of recruitment into the study was perceived to be very high. Of patients screened but not 
enrolled (eligible based upon booked procedure and time) the most common reasons for 
exclusion were: 
1) use of psychoactive medications I narcotics within one week of the study 
2) use of preoperative sedative 
3) language I communication difficulties. 
During this time period 88 subjects were recruited and randomised to the study. 
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There were no subjects over the age of 65 and therefore according to predetermined 
stratification guidelines all randomization envelopes were removed sequentially from the 
age under 65 box. The break down of subject recruitment and retention including those 
subjects with incomplete data collection sets are depicted in figure #3 .1. 
48 
Subject Enrollment and Retention 
Figure #3.1 Subject retention while enrolled in the trial collection period. 
Number (N) of subjects not discharged and the number of completed outcome 
assessments for each collection period 
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Subject Dropout 
Of the 88 patients entering the trial, four withdrew or were withdrawn from the 
trial before its completion. Two were assigned to the control group-propofol (Group A) 
and 2 were assigned to the intervention group-midazolam (Group B). Outcome 
assessments from these subjects were not included in the final analysis. The baseline 
data on these 4 subjects was collected for separate analysis. The details of subject 
dropout are provided. 
Of the 4 subjects who did not complete the study, one patient was withdrawn due 
to intraoperative surgical complications (inadvertent bowel perforation with a subsequent 
3-hour repair and colostomy). The duration of surgery and anticipated complicated 
postoperative course were cited as reasons for withdrawal. The remaining three subjects, 
who withdrew, did so in the Post Anesthesia Care Unit (PACU). Two of these patients 
refused to complete the outcome assessments due to post-operative nausea and I or 
vomiting. The third subject refused to complete the outcome assessments due to 
uncontrolled pain. These patients were approached 15 minutes after initial refusal to 
offer continuance in the study. All three subjects declined further study participation. 
Subject retention 
Eighty-four subjects completed the trial. Outcome assessments and data were 
collected every thirty minutes in the P ACU until discharge. The earliest discharge (in 
accordance to IWK Health Centre institutional standards) was at 60 minutes. Of the 84 
subjects who completed the trial, 10 subjects had 12 incomplete data collections (2 
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subjects had 2 incomplete data sets) prior to discharge from PACU. The last data set was 
completed at 120 minutes. These missing outcome assessments were evenly divided 
between the propofol control group and the midazolam intervention group. 
At 30 minutes, 95.2% of subjects (eighty of a possible 84) had completed 
outcome assessments- 39 in the propofol control and 41 in the intervention midazolam 
group. At 60 minutes, 100% of subjects (eighty-four of a possible 84) had completed 
outcome assessments- 42 in the propofol control and 42 in the intervention midazolam 
group. At 90 minutes, there were 48 subjects still available for assessment in PACU. Of 
the 48 subjects, 95.8% or 46 outcome assessments were completed- 26 in the propofol 
control and 20 in the midazolam intervention group. There were 10 subjects still in 
PACU at 120 minutes. Of these 10, 60% or six had complete outcome assessments, 2 in 
the propofol group and 4 in the midazolam group. 
Data up to and including the 60-minute data collection were included in the 
analysis. Eighty-four of the 84 subjects had complete data sets at the 60-minute data 
collection point. All data collection periods up to and including the 60-minute period had 
enough data collected for each subject to meet our sample size requirement of 35 per 
group. Because of the loss of subjects on discharge, analysis of data after this 60-minute 
data collection point lacks power and is more prone to bias due to potential differential 
loss across groups. 
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Baseline Demographics 
Of the 84 patients who completed the trial, 42 received midazolam coinduced 
general anesthesia and 42 standard propofol induction. Of the 4 subjects who did not 
complete the study, 2 were randomized to the midazolam coinduction group and 2 to 
standard propofol control. Comparison of the baseline characteristics of those who 
completed the study by randomized group is provided in table 3.1. 
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Table 3.1 Comparison of Baseline Demographics by Randomized Group 
Propofol Midazolam 
Control Coinduction 
N=42 N=42 
Mean +/-SD Mean +/-SD 
Age (years) 32.9+/-6.4 31.7+/-6.2 
Weight (kg) 68.9+/-12.9 71.5+/-17.4 
N(%) N(%) 
ASA class I 24(57.1) 28(66.7) 
class II 18(42.9) 14(33.3) 
Procedure: 
Diagnostic Laparoscopy 20(47.6) 21(50.0) 
Laparoscopic TIL 22(52.4) 21(50.0) 
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Of the four subjects who did not complete the study, baseline demographics were 
collected and are shown in table #3 .2. These demographics are compared to those 
subjects who did complete the study. There does not appear to be any difference with 
respect to age, weight, and ASA status or procedure type to distinguish this group from 
those who did complete the study. 
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Table 3.2 Baseline Comparison of Subjects whom Withdrew to those 
Completing the Study. 
Withdrawn from Completed 
Study Study 
N=4 N=84 
Mean +/-SD Mean +/-SD 
Age (years) 27(+/-2.9) 32.3(+/-6.3) 
Weight (kg) 66.5(+/-8.6) 70.3(+/-15.3) 
N(%) N (%,) 
ASA class I 3 (75%) 52(61.9) 
class II 1(25%) 32(38.1) 
Procedure: 
Diagnostic Laparoscopy 3(75%) 41(48.8) 
Laparoscopic TIL 1(25%) 43(51.2) 
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As shown in table #3.1, the groups were comparable with respect to all baseline 
characteristics including age, weight, and American Society of Anesthesiologists (ASA) 
physical classification. The average age was 32.9 years for the control group versus 31.7 
in the midazolam group. The average weight was 68.9kg compared to 71.5kg. Similarly 
the type of operative procedure was evenly distributed in both groups. Of the 84 
operative procedures, there were 41 diagnostic laparoscopies, 20 in the propofol control 
and 21 in the midazolam group. There were 43 laparoscopic tubal ligations with 22 in 
the propofol group and 21 in the midazolam group. 
OUTCOME MEASURES 
Intraoperative Variables 
Figure 3.2 shows the group averages, at different time points, for a range of 
hemodynamic measures including heart rate (beats per minute) and systolic and diastolic 
blood pressure (mmHg). Analysis by Student's t-Test for independent continuous data 
showed no statistically significant difference between the two groups. 
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Figure 3.2 Intraoperative Hemodynamic Profile By 
Randomized Group. No significant difference noted at any 
measurement time points in heart rate, systolic or diastolic 
blood pressure 
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Groups were assessed with respect to various intraoperative variables (see table 
#3.3). Analysis was done using Student's t-Test for continuous data and Chi-Square I 
Fisher's Exact testing for categorical data. The purpose of these analyses was to 
determine whether there were any unexpected differences in the standardized general 
anesthetics administration or outcomes relating to the characteristics of the anesthetics 
that the two groups of patients received. 
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Table #3.3 Comparison of Intraoperative Variables based upon Group Randomization 
Propofol Midazolam 95%, 
Control Coinduction Confidence 
N=42 N=42 Intervals 
Mean+/-SD Mean+/-SD (for the 
difference) 
Duration of 41 +/-16 43+/-16 -0.08, 0.005 
Anesthesia (min) 
Total Propofol 2.12+/-0.23* 1.19+/-0.32* 0.81, 1.04 
Dose (m2fkg) 
Total Fentanyl 2.24+/-.44 2.21+/-.47 -0.17, 0.22 
Dose (meg/kg) 
(for 
N(%) N(%) Relative Risk) 
Subjects Failing 
Induction (RR 1.0) 
Requiring 5 (11.9) 5 (11.9) 0.31, 3.20 
Supplemental 
Propofol 
(RR 1.09) 
Received NSAIDS 35 (83) 38 (90) 0.92, 1.28 
in OR 
Received (RR 0.94) 
Ondansetron 17 (40.5) 16 (38.1) 0.55, 1.60 
Prophylaxis 
(RR 0.67) 
Occurrence of 3 (7.1) 2 (4.8) 0.67, 3.79 
Adverse Events 
* indicates p < 0.000 
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Table 3.3 demonstrates that both groups received comparable standardized 
anesthetics including anesthetic duration, dosages of fentanyl, prophylactic anti-emetic 
( ondansetron) and non-steroidal anti-inflammatory drugs (NSAIDS). This would support 
that there were no unrecognized confounding seen based upon these variables. The mean 
amount of propofol received was statistically significant as would be expected based 
upon study design and group randomization (p<O.OOO). 
The number of patients(%) failing induction requiring supplemental propofol was 
exactly the same 5(11.9%) per group. This would indicate similar reliability of induction 
between the two techniques. The rate of failed induction (11.9%) is as expected or better 
as this study utilized the ED 50 dosages (ED 50 - estimated dosage to induce 50% of 
patients) for anesthetic induction agents used. The improved rate of failed induction 
likely can be accounted for by the addition of narcotic (fentanyl) during induction for 
both groups. Fentanyl was used primarily for its analgesia during surgery also has 
synergistic and additive effects on anesthetic induction. It is therefore often given at time 
of induction to improve quality and reliability of induction. 
The incidence of adverse events was also recorded and analyzed for both groups. 
There were 3(7.1%) in the propofol control group compared to 2(4.8%) in the midazolam 
coinduction group, which did not meet statistical significance (p= 1.0). These adverse 
events are not uncommon and were felt to be minor in nature. They consisted of two 
intraoperative episodes of bronchospasm (increased airway pressures PaW> 35cmH20), 
two intraoperative episodes of bradycardia (heart rate <40bpm) and one episode of 
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hypertension I tachycardia with carbon dioxide insufflation of the peritoneum (responded 
to deepening anesthesia). 
Post Anesthesia Care Unit Variables 
Groups were also assessed with respect to various post anesthesia care unit 
(P ACU) characteristics. These included standard assessments such as Aldrete Score and 
length ofPACU stay. The requirements for postoperative analgesia and anti-emetic 
(PONV) rescue medications (see table #3.4) were also assessed. There were no 
statistically significant differences between groups in any of these variables based upon 
Students t-Test or Chi-square testing as appropriate. 
All subjects were asked upon arrival in the P ACU and just prior to discharge 
about recall of intraoperative events. No subjects reported any memories of the operative 
procedure itself or any intraoperative recall after "going to sleep". 
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Table# 3.4 Comparison of Post Anesthesia Care Unit variables based upon Group 
Randomization 
Propofol Midazolam 95% 
Control Coinduction Confidence 
N=42 N=42 Intervals 
Mean +/-SD Mean +/-SD (for the 
difference) 
Morphine Dose 0.13+/-.10 0.13+/-.11 - 0.042 ' 0.049 
Received (mg/kg) 
Length of P ACU 
stay 91+/-37 83+/-32 -0.07, 0.23 
(min) 
(for 
N(%) N(%) Relative Risk) 
Aldrete ~7 on (1.03) 
Arrival 35 (83.3) 36 (85.7) 0.86, 1.24 
Received (0.92) 
Ondansetron 13 (31.0) 12 (28.6) 0.48, 1.78 
Rescue 
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Table 3.4 demonstrates that the PACU stay for both groups were similar with 
respect to all variables including markers of physiologic recovery (Aldrete Score) and 
rate of postoperative nausea and vomiting ( ondansetron rescue). The average length of 
stay in PACU was 1 hour and 31 minutes (+/-37) for the propofol control group and 1 
hour and 23 minutes (+/-32) for the midazolam coinduction group. Similar numbers of 
subjects in both groups who received an Aldrete score of 7 or greater and /or received 
ondansetron rescue for PONY. 
Assessment of Neuropsychological Recovery 
The Digit Symbol Substitution Time and the Treiger Dot Test results conducted 
preoperatively and postoperatively every thirty minutes once an Aldrete Score of 7 or 
greater was attained. Greater than eighty percent of subjects in both groups had an 
Aldrete Score of7 or greater an arrival in PACU. All patients had an Aldrete Score 7 or 
greater at time of first assessment (30 minutes). The five Visual Analogue Scales were 
also scored preoperatively and every thirty minutes concurrently with the objective 
measures. 
The data were analyzed initially using Student's t-Test and secondarily with a 
general linear model analysis of covariance (ANCOVA) for repeated measures. Initial 
statistical analysis of cognitive function was completed using Student's t-Test for 
independent group means. The results shown in Figure# 3.5 are for the initial 
preoperative or baseline assessment. Student's t-Test was also used to compare the 
groups at the 30-minute (table 3.6) and 60-minute (table 3.7) intervals. 
63 
The repeated measures analysis using Analysis of Covariance (ANCOV A) 
adjusting for baseline preoperative scores utilized a full factorial model with simple 
within subject contrasts. The model included time as a within subject factor and group 
randomization as a between subject factor. The data were analyzed as previously noted 
up to 60 minutes using the preoperative value for outcome of interest as covariate in each 
case. Table 3.8 summarizes the statistical significance levels of cognitive recovery 
assessments. Tables 3.9 to 3.11 provide more detailed information with respect to the 
Analysis of Covariance (degrees of freedom, mean square, F value etc.) for each 
cognitive test. 
As expected all these assessments except the VAS for anxiety showed a 
significant difference for all measures over time in both groups i.e. "wearing off' effect 
of the drug over time. This is expressed in the "Time" row in tables #3.8 through to 
#3.11 
A test for interaction was also performed as shown in the "Time by Group 
Randomization" row in tables #3.8 to #3.11 which specifically assessed whether there was 
a particular time point (i.e. 30-minute versus 60 minute measure) where the 
neuropsychological test results were more influenced by the randomized group 
assignment. There was no difference in the neuropsychological test results even at earlier 
time points based upon group randomization. 
When analyzed for between subject factors for group randomization there was no 
difference in the neuropsychological assessments based upon whether the patient 
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received midazolam coinduction or propofol alone. This is expressed in the row "Group 
Randomization" in tables #3. 8 through to #3 .11. 
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Table# 3.5 Student's t Test comparing Neuropsychological Assessments between 
Midazolam and No Midazolam (control) groups at baseline (preoperative) 
Mean Std 
Deviation 
Significance 95% Confidence 
a a Level Interval ~ ~ 
- - - - (of the = = = e p ~N i1f ~ .... difference) "0"'!!' "0 = ·• II .... = ~z UZ ~ u 
DSST 64.6 58.9 12.1 12.4 0.03* -11.12, -0.46 
TDT 2.8 4.2 2.9 3.6 0.06 -0.03, 2.79 
VASt 1.4 1.5 1.5 1.9 0.83 -0.66, 0.82 
VAS2 0.8 0.8 1.5 1.1 0.97 0.56, 0.55 
VAS3 0.5 0.7 0.3 0.7 0.07 -0.02, 0.44 
VAS4 3.6 3.1 2.5 2.2 0.36 -1.50, 0.54 
VAS5 1.2 1.2 1.3 1.2 0.93 -0.57, 0.52 
* indicates p< 0.05 
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Table# 3.6 Student's t Test comparing Neuropsychological Assessments between 
Midazolam and No Midazolam (control) groups at 30 minutes Postoperative 
Mean Std 
Deviation 
a a Significance 95% Confidence 
- -
Level Interval ~ f=" ~ = -~ 
-
.. =~ 
..... ~ = ..... p (of the difference) ~ II ~ = "OZ ~z "'0  
.... u .... u ::g ::g 
DSST 50.6 46.5 10.4 11.0 0.09 -8.92, 0.62 
TDT 8.9 10.8 6.7 7.4 0.23 -1.25, 5.0 
VASl 6.6 5.8 1.9 2.0 0.10 -1.6, 0.14 
VAS2 4.2 4.2 2.5 2.6 0.94 -1.10, 1.19 
VAS3 5.1 4.8 2.1 1.8 0.52 -1.18, 0.60 
VAS4 2.8 2.3 2.2 1.7 0.23 -1.42, 0.35 
VAS5 5.3 5.2 1.4 1.7 0.67 -0.81, 0.53 
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Table# 3.7 Student's t Test comparing Neuropsychological Assessments between 
Midazolam and No Midazolam (control) groups at 60 minutes Postoperative 
Mean Std 
Deviation 
a a Significance 95% Confidence 
- -
Level Interval 
= = = = 
- -= 
... 
= 
... (of the difference) ~ ..... ~ ..... p = = "t:: = "t:: = .... u .... u ~ ~ 
DSST 55.7 51.8 10.5 12.7 0.12 -9.01, 1.11 
TDT 7.1 7.9 5.8 7.3 0.56 -2.02, 3.68 
VASt 4.5 4.5 10.5 12.7 0.89 -1.11,0.97 
VAS2 2.9 3.2 2.0 2.4 0.57 -0.68, 1.23 
VAS3 3.3 3.7 2.0 1.8 0.40 -0.48, 1.18 
VAS4 1.9 2.2 1.6 1.8 0.40 -0.42, 1.04 
VAS5 4.06 4.01 2.01 1.95 0.93 -0.90, 0.82 
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Table # 3.8 Summary of Significance (p) Levels for Outcome Variables up to 60 Minutes by Repeated Measures Analysis of 
Covariance Adjusted for Baseline 
VASl VAS2 VAS3 VAS4 VAS5 
DSST TDT 
Level of Level of Level of Level of Level of 
drowsiness confusion coordination anxiety Sedation 
Time 0.01* 0.05* O.OOt O.OOt O.OOt 0.32 O.OOt 
Timex 
Group 0.50 0.30 0.33 0.65 0.15 0.11 0.98 
Randomization 
Group 
Randomization 0.78 0.94 0.22 0.76 0.92 0.58 0.67 
Tests of within subjects factors for time and between subjects factors for group randomization. Full factorial model, 
simple within subjects contrasts. *indicates p< 0.05 t indicates p< 0.01 
69 
Table # 3.9 Analysis of Covariance Repeated Measures Adjusted for Baseline Measures 
for the Digit Symbol Substitution Test and Trieger Dot Test Outcomes up to 60 minutes 
Digit Symbol Substitution Trieger Dot 
Test Test 
df MS F p df MS F p 
Time 1 119.6 6.35 0.01* 1 74.44 4.13 0.05* 
TimeX Group 1 8.55 0.45 0.50 1 19.00 1.09 0.30 
Randomization 
Group Randomization 1 0.45 0.08 0.78 1 0.17 0.01 0.94 
* indicates p< 0.05 t indicates p< 0.01 
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Table# 3.10 Analysis of Covariance Repeated Measures Adjusted for Baseline Measures 
for the Visual Analogue Scale Outcomes up to 60 Minutes 
VASl VAS2 
Level of Drowsiness Level of Confusion 
df MS F p df MS F p 
Time 1 79.16 34.08 o.oot 1 49.80 28.80 O.OOt 
TimeX Group 1 2.28 0.98 0.33 1 0.37 0.22 0.65 
Randomization 
Group Randomization 1 5.26 1.54 0.22 1 0.45 0.09 0.76 
* indicates p< 0.05 t indicates p< 0.01 
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Table # 3.11Analysis of Covariance Repeated Measures Adjusted for Baseline Measures for the Visual Analogue Scale 
Outcomes up to 60 minutes 
VAS3 VAS4 VAS5 
Level of Co-ordination Level of Anxie~ Level of Sedation 
df MS F p df MS F p df MS F p 
Time 1 47.21 37.00 O.OOt 1 1.54 1.02 0.32 1 53.50 41.35 O.OOt 
TimeX Group 1 2.70 2.11 0.15 1 4.03 2.68 0.11 1 0.00 0.00 0.98 
Randomization 
Group 1 0.003 0.01 0.92 1 0.81 0.31 0.58 1 0.45 0.18 0.67 
Randomization 
* indicates p< 0.05 t indicates p< 0.01 
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Pharmacoeconomics 
Comparison of intravenous anesthetic induction agent drug cost (based upon the 
average drug dosages used per group) for induction of general anesthesia was completed. 
The drug cost was obtained from the pharmacy director (personal communication 68) of 
IWK Health Centre formulary list prices for 2001. The control group received an 
average dose ofpropofol2.12 mg/kg (145mg) for an estimated induction drug cost of 
$3.25. The midazolam coinduction group received an average dose ofpropofol1.19 
mg/kg (85mg)- cost of$1.62 and midazolam 0.02mg/kg (1.45mg)- cost of$0.52 for a 
total drug cost of$2.14. The induction drug cost savings based upon the coinduction 
technique was $1.11 per patient. 
73 
CHAPTER4 
Discussion and Conclusions 
The purpose of this study was to assess the effect ofmidazolam- a short acting 
benzodiazepine on general anesthesia recovery. We wished to assess whether a low dose 
of midazolam as used in a co induction technique altered the recovery characteristics of 
patients receiving this type of general anesthesia induction. This was compared to 
standard propofol induction of general anesthesia. We specifically wished to assess 
cognitive recovery as assessed by objective neuropsychological testing. 
We also wished to look at other secondary outcomes to assess the similarity of the 
two anesthetic techniques with respect to anesthetic quality. These outcomes included 
quantitative and qualitative assessments of clinical parameters of general anesthesia such 
as adverse events rate, failure of induction and postoperative analgesia requirements. 
These were included to look for possible subtle clinical differences between the two 
techniques of induction that had not been previously recognized. Such differences 
between the two techniques might confound any study differences. The secondary 
outcomes were also included to support or refute previously hypothesized benefits of the 
coinduction technique. We however acknowledge that conclusions cannot be made upon 
these findings but may suggest a relationship that would require further study or 
evaluation to prove a causal relationship existed. 
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The study results will be discussed with respect to these objectives. Where 
possible the results will be compared to previously published work. In addition where 
possible clinical implications of the study results will be discussed. 
REVIEW OF RESULTS 
During the 5-month study period 88 subjects were enrolled and 84 patients 
completed the study. The data on the four subjects who did not complete the study was 
collected and analyzed. This group of patients did not appear to be demographically 
different from those subjects who did complete the trial. 
Of the 84 subjects who did complete the trial, exactly half ( 42) were randomized 
to the midazolam coinduction intervention group and half ( 42) to the propofol control 
group. The a priori sample size estimate of 35 was therefore exceeded for both groups at 
all time periods throughout the study. Data was collected on the subjects after 60 minutes 
for potential further secondary analysis of predictors of "late stayers" or those who were 
not discharged after the expected 1 hour recovery time period. 
As expected with appropriate randomization techniques the groups were 
demographically similar with respect to all base line characteristics including age, weight 
and American Society of Anesthesiologists classification. The type of laparoscopic 
procedure completed during the operation was also similar between groups. 
While we feel it important to demonstrate the clinical similarity of the groups at 
baseline we did not look at the statistical differences. It is felt that the risk of 
unrecognized confounding that differences in age, weight, health status and procedural 
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differences is minimized by randomization. We did compare intraoperative and 
postoperative parameters to assess statistical differences. Differences would be 
particularly important if unexpectedly one of the groups experienced more postoperative 
pain with increased postoperative narcotic requirements. Any differences in cognitive 
function as assessed by testing may inadvertently be attributed to midazolam when 
possibly it may be associated with the higher narcotic administration in that group. Such 
a finding would be of clinical concern also, as it would have to be explored as to whether 
the two anesthetic techniques were indeed equivalent with respect to this clinical 
endpoint. 
Age was felt to be an important possible source of confounding and so therefore 
was stratified for. There were no subjects enrolled in the age over 65 years and therefore 
no patients were randomized from this stratum. This likely is due to the disease 
processes I clinical indications within the group of patients that undergo diagnostic 
laparoscopy I tubal ligation. Clinically these patients are usually young, pre-menopausal 
and ovulating. Patients 65 and older do not fit this clinical description and are likely not 
to present for these types oflaparoscopic surgery. As a result of this we cannot 
generalize our study results to patients over 65 years. This group should be assessed in 
subsequent studies before any conclusions for this age group can be made. 
Intraoperative Variables 
Intraoperative variables were assessed during anesthetic induction of general 
anesthesia and throughout the duration of the operative procedure. There were no 
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differences in hemodynamic parameters as measured immediately post induction I 
intubation and throughout the procedure. Previously published work indicates 
inconsistent hemodynamic response during coinduction. 
McClune et al (22) and Elwood et al (28) found no statistically or clinically 
important difference in blood pressure or heart rate response. Miller et al ( 49) indicates 
that hemodynamic response to induction and tracheal intubation were similar in the 
placebo and two low dose ranges of midazolam used during a midazolam TIV A 
coinduction technique. The high dose midazolam coinduction group (0.045mg/kg) in this 
same study however showed a beneficial lack of blood pressure response to intubation. 
Delucia et al (27) indicate that there was a greater fall in blood pressure post induction 
and less increase in blood pressure response to intubation. It is unclear if this occurred in 
both the low and/or high dose midazolam groups used in this study. These findings are 
somewhat contradictory in clinical desired effect. It is desirable to minimize a large 
blood pressure response to intubation, but it is undesirable to have a greater fall in post 
induction blood pressure possibly indicating less hemodynamic stability. The current 
study found that the hemodynamic response was similar between the two study groups 
and I am therefore unable to support to the claims that midazolam coinduction may 
provide greater hemodynamic stability. 
The dose used for general anesthesia induction is the ED 50 of the specific drug 
used. Therefore by definition up to 50% of subjects may fail the initial drug dose and 
require supplemental induction drug. This study used the ED 50 for propofol alone and 
the ED 50 ofmidazolam-propofol as determined by isobolographic and probit analysis. 
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The number of subjects failing initial induction dose (clinically defined prospectively) 
was exactly the same (11.9%). The low number of subjects failing induction is accounted 
for by the use of narcotic administration during the induction sequence. Fentanyl, when 
used as an induction agent acts additively with propofol (67) and synergistically with 
midazolam (16). The study is unable to support the hypothesis ofVinik and others 
(25,26) that midazolam coinduction provides less variability and more precise anesthetic 
induction sequence 
The duration of the operative procedures, total intraoperative narcotic dose, 
proportion of subjects receiving non-steroidal anti-inflammatory drugs (NSAIDS) and 
postoperative nausea and vomiting prophylaxis (PONV) was comparable between the 
standard propofol and the midazolam coinduction group. This supports that the 
standardized anesthetic protocol was followed and that the exposure to intraoperative 
drugs including inhalation anesthetic volatile vapour was similar for a comparable time 
period. The total dose ofpropofol (mg/kg) was different between the two groups as 
expected based upon the randomized group assignment. The total drug dose of propofol 
was slightly higher than that assigned based upon group randomization due to rounding 
up to the nearest 1 Omg. 
During general anesthesia patients are exposed to large numbers of drugs. The 
use of a co induction technique requires the exposure of yet another drug. Theoretically 
this may expose patients to increased undesired drug interactions. Also during a 
coinduction technique midazolam is administered prior to the administration of propofol 
often while the patient is being preoxygenated. There is potential for sedation during the 
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pre-oxygenation period and potential risk of impairment of de-nitrogenation if there is 
unexpected respiratory depression. The rate of minor adverse intraoperative events was 
low: 3 patients (7.1%) in the control group compared to 2 patients (4.8%) in the 
intervention group. This is comparable to previously published event rates (69). These 
supports the suggestion ofVinik et al (25,26) regarding the safety ofmidazolam 
coinduction compared to routine propofol induction. 
Postoperative Variables 
Postoperative variables were collected once the subject was admitted to the Post 
Anesthesia Care Unit (PACU) again as secondary outcome measures. These consisted of 
standard P ACU recovery assessments and assessment of postoperative pain (by narcotic 
requirements while admitted to the unit) as well as rate of postoperative nausea and 
vomiting (as determined by ondansetron anti-emetic rescue) between the two groups. 
There was no significant difference between the two study groups with respect to 
percentage of patients who had attained an Aldrete Score of 7 or greater on admission 
(85.7% midazolam compare to 83.3% control). There was also no significant difference 
in the length of stay in the P ACU between the two groups. These measures of 
physiological recovery suggest similarity between the two anesthetic techniques with 
respect to crude measures of anesthetic recovery. These findings agree with earlier 
published work of Miller et al (49) and Elwood (28). 
The total drug dose of morphine (mg/kg) received by the two groups was the 
same (0.13mg/kg). The percentage ofpatients who received ondansetron anti-emetic 
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rescue was also comparable (28.6% midazolam compared to 31% control). This suggests 
similarity in postoperative clinical parameters of postoperative pain and postoperative 
nausea and vomiting. 
Neuropsychological Testing 
The neuropsychological test battery consisted of the Digit Symbol Substitution 
Test (DSST), the Trieger Dot Test (TDT), and 5 Visual Analogue Scales (VAS). These 
were administered preoperatively, as a baseline measure and every 30 minutes in P ACU 
until discharge once an Aldrete Score of 7 or greater was attained (indicating physiologic 
stability). These scores were initially analyzed using Students t-test for independent 
grouped means. T -tests were conducted on the baseline measures and on the 30 and 60 
minutes measures. While we felt that baseline demographics did not need statistical 
comparison, we did wish to look at the baseline cognitive tests, as any difference would 
have implications on the interpretation and clinical relevancy of any group differences 
after the intervention. The initial statistical analysis revealed the only significant 
difference between the two groups on neuropsychological testing actually occurred in the 
baseline measure on the DSST (64.6 midazolam intervention compare to 58.9 control 
symbols substituted p = 0.03 with 95% CI for difference -11.12 to -0.46). This 
unfortunately indicated that there was a baseline difference in cognitive function as 
measured by the primary outcome assessment tool between the two groups prior to the 
study intervention. The other secondary measures in the test battery did not show any 
difference at the baseline. 
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A second issue of multiple comparisons was also recognized at this point in time. 
Multiple comparisons can lead to a much higher probability of making a Type I error (a= 
0.05 + 0.05 + 0.05+ 0.05 etc). Statistically significant results and scientific conclusions 
must therefore be viewed cautiously when utilizing multiple comparisons over time on 
the same subjects. To minimize the possibility of making a type I error when conducting 
multiple analyses one may adjust the a downwards (commonly by dividing the a by the 
number of comparisons). Another approach is the Bonferroni method whereby the 
critical value fort to be declared significant is increased (the amount increased depending 
on the number of comparisons). 
However it was felt to be more appropriate to utilize an Analysis of Covariance 
using a repeated measures general linear full factorial model with simple comparisons. 
Utilizing this statistical method also allowed adjustment for the baseline difference in the 
preoperative neuropsychological test results (as a covariate). It also allowed for within 
subject comparison of the effect of time on the neuropsychological test results. The 
between subject comparison was for group randomization to assess the effect of the 
intervention. 
Analysis of Covariance as described revealed that all measures of cognitive 
function (except the V AS#4 for anxiety) had a statistically significant difference in effect 
over time (within subject comparison). This would be as expected as there would be a 
clinical "wearing off' of the general anesthetic drug effects over time as the patient 
recovered in the PACU. 
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Analysis of Covariance by group randomization (between subjects comparison) 
analyses revealed there was no difference in any of the tests of neuropsychological 
function. Specifically the Digit Symbol Substitution Test, our primary outcome variable 
did not reveal a difference at the 60 minute assessment and had a significance level of p = 
0.78. The control average score was 51.8 symbols substituted while the midazolam 
intervention group had an average score of 55.7. The mean difference in DSST scores at 
60 minutes was- 3.9. The a priori clinically significant difference was 13 symbols 
substituted. The 60-minute DSST t-Test 95% confidence interval for the difference was 
-9.01 to 1.11. The confidence interval crosses zero which allows us to be more 
confident that the data is consistent with a possible population mean difference of zero. I 
also note that the width of the confidence interval is narrow and the upper and lower 
bounds do not include a clinically relevant difference in the score for the DSST. This 
allows us to interpret this negative trial as having sufficient power to exclude such a 
difference. The lack of group differences on the secondary measures of 
neuropsychological testing (TDT and VAS scores) supports this assertion. 
Of note, comparison was also made utilizing time and group randomization 
together specifically assessing whether there was a particular time point where the 
neuropsychological testing was more influenced based upon group randomization. There 
was no difference in the neuropsychological test results even at earlier time points based 
upon group randomization. 
82 
Subjective Assessment of Cognitive Recovery 
The VAS #4 score (out of 10 em) for anxiety did not show a significant effect 
over time. This could be explained by the apparent low overall level of anxiety as judged 
by the subject's preoperative ratings (3.6cm midazolam compared to 3.1 em control 
(preoperative) which remained low both at 30 minutes-2.8cm compared to 2.3cm and 
1.9cm compared to 2.2 at 60 minutes. 
As a measure of internal validity of the VAS assessing the patient's perception of 
level of consciousness, two scales asking the same question were included (VAS #1 for 
drowsiness and VAS #5 for sedation). The scores were similar on both questions over 
the 3 time periods assessed. 
The VAS assessments were included to measure the patient's ability to 
subjectively assess their cognitive recovery. This was measured by asking about feelings 
of confusion (VAS #2) and of coordination (VAS#3). These assessments revealed that 
neither measure had returned to baseline score at the time of discharge. Confusion: 
0.8cm midazolam and 0.8cm control (baseline) compared to 2.9 midazolam and 3.2cm 
control (60 minutes). Coordination: 0.5cm midazolam and 0.7cm control compared to 
3.3cm midazolam and 3.7cm control (60 minutes). This lack of return to baseline agreed 
with the objective DSST and TDT assessments. DSST: 64.6 score (midazolam): 58.9 
score (control) at baseline compared to 55.7 (midazolam): 51.8 (control) at 60 minutes. 
TDT: 2.8 missed (midazolam): 4.2 (control) at baseline compared to 7.1 missed 
(midazolam) : 7.9 (control) at 60 minutes. These findings suggest that patients may 
indeed be able to judge their own degree of cognitive impairment post general anesthesia. 
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Economics and Coinduction 
Comparison of the anesthetic induction agent drug cost based upon the average 
drug dosages used per group was completed. The induction drug cost savings based upon 
the smaller total drug cost of a co induction technique was $1.11 per patient. This 
calculation likely is not a realistic assessment of cost differences between the two 
techniques. This does not account for the added cost of an additional syringe, 
hypodermic needle or professional time needed to prepare the medication. There may 
also be associated drug wastage costs as propofol is supplied in 200mg single dose vial. 
The average propofol induction dose for single agent technique was 145mg, while the 
average propofol dose in the coinduction group was 85mg. Theoretically, the contents of 
the single dose vial of propofol should be discarded after each case. Midazolam may be 
used in more than one case as it is supplied as multi-dose vial. Practically, if prepared in 
a sterile manner most clinicians do not discard the contents of the opened vial (personal 
communication with department colleagues). If the remainder of the propofol vial were 
discarded as the manufacturer suggests then there would be no drug cost savings using 
the coinduction technique. There actually would be an extra drug cost associated with 
using midazolam. 
The potential cost associated with earlier discharge from P ACU was assessed. 
The difference of an 8-minute earlier discharge in the midazolam coinduction group was 
not statistically significant and is likely not clinically significant. It does however 
represent a 10% overall reduction (91 versus 83 minutes) in the time spent in the PACU. 
The calculation of potential cost savings in earlier discharge from P ACU is complex. 
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There is local data on the cost per patient per hour admitted in the P ACU ($65. 00 per 
hour). Based upon cost per patient per hour admitted to P ACU a difference of 8 minutes 
a saving of $8.67 would be estimated (personal communication# 70). 
Patient discharge from P ACU is influenced by factors other than the actual time 
that the patient is physiologically ready for discharge. Discharge from Canadian P ACU' s 
is no less than 1 hour after general anesthesia. Time to discharge may also be dependant 
upon the unit activity (if the PACU nurses are otherwise busy) and whether or not the 
responsible escort for the patient is available for discharge I transport. The other 
confounding factor on P ACU cost containment arises from P ACU staffing practice. 
Staffing is based upon the case load per day with a minimum number of nurses per 
booked number of cases. The P ACU has to be staffed by at least 2 nurses, require a 
minimum number of hours that can be worked per shift and are usually required to 
remain in the P ACU unit until the booked shift is completed. This requirement maybe 
regardless of the presence of recovering patients in the unit. Earlier discharge within the 
Canadian health care system does not automatically mean that the nursing staff hours will 
be reduced. The likelihood of significant health care cost containment with respect to 8 
minutes earlier discharge ($8.67) plus possible drug savings ($1.11) is felt to be 
negligible at best. 
Intraoperative Awareness 
There was no incidence of intraoperative awareness I recall in either study group 
during the study. This would be in keeping with previously published reports of 
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intraoperative awareness incidence (0.1- 0.2% by Lui et al (51)). In a study of this size 
one might expect one possible report of awareness. Due to the rarity of such an event the 
sample size estimated to show a protective effect of midazolam during co induction would 
be prohibitively large. We are unable to comment on the protective effect of midazolam 
on intraoperative awareness as suggested by Miller et al (49). 
CONCLUSIONS 
In conclusion, this study shows that there is no clinically important difference in 
cognitive recovery, as assessed by the Digit Symbol Substitution Test, in ambulatory, age 
under 65 years, gynecologic patients undergoing elective laparoscopic procedures of 
short duration within patients receiving midazolam during a coinduction technique 
compared to standard propofol induction. These results appear to be supported by 
secondary measures of cognitive function using the Trieger Dot test and Visual Analogue 
Scales. 
The assessment of other post anesthesia recovery features including Aldrete 
Score, length of P ACU stay appear to be similar. Features such as postoperative nausea 
and vomiting and postoperative narcotic requirements are similar between the standard 
induction technique and coinduction. We therefore suggest that both standard recovery 
room assessments and cognitive assessments appear not to be different between the two 
induction techniques. There does not appear to be any adverse effects on recovery using 
a coinduction technique using very low dose benzodiazepines. 
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The study supports the idea of similarity between a standard induction and a 
coinduction technique with respect to all other intraoperative clinical parameters such as 
induction reliability, adverse events, and hemodynamic stability. The possible benefits 
with respect to induction reliability, safety and hemodynamic stability were not 
demonstrated. Firm conclusions with regard to these parameters cannot be reached from 
the current study and need to be formally assessed in future trials. The hypothesized 
economic benefits of drug costs or hospital costs (P ACU I unplanned admission etc) were 
also not demonstrated in this trial. The last hypothesized benefit of possible 
intraoperative awareness could not be assessed due to the rarity of the event. 
Finally, I would conclude that the coinduction anesthetic technique appears to be 
equivalent to standard single agent induction, specifically with respect to cognitive 
recovery, but also generally compared to other qualitative general anesthesia features. 
Practically, if individual anesthesiologists based upon the unproven belief that there are 
benefits of a coinduction technique such as an intraoperative recall protection then there 
do not appear to be any adverse post anesthesia recovery cognitive affects to deter its use. 
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CHAPTERS 
Problems and Limitations 
This chapter contains a review of the limitations of this study including 
methodological issues identified after the study completion. This chapter will also 
review the unexpected difference in preoperative group scores for the Digit Symbol 
Substitution Test, the primary outcome measure. The choice of the clinically significant 
difference on this test will also be discussed with respect to the study conclusions. These 
discussions will address possible implications for future research in this area. 
The implications of the prolonged time period taken to complete, analyze and 
disseminate the results of this study (including this thesis) will be discussed. The clinical 
relevance of the coinduction technique to current clinical practice as opposed to practice 
in 1995 will be discussed. The results of this study will be compared to other similar 
studies published in the interval between conception and dissemination of this study. 
Blinding 
This study is a double blinded trial such that neither the investigator completing 
the outcome assessments nor the patients were aware of group assignment. The 
anesthesiologist administering the drugs however was aware of the group assignment and 
drug administration. One might argue that this therefore is an open label, blinded 
endpoint study. 
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The unblindedness of the administering anesthesiologist could have been a 
potential source of bias. Despite the study requirement of administering a standardized 
anesthetic protocol, which included specific volatile inhalation agent endpoints, there is a 
possible range of concentrations that the patient could have received. At the time of this 
study we were unable to measure dose of inhalation agent used. It is possible that an 
unblinded anesthesiologist could have resulted in systematic differences in concentration 
of the inhalation agent possibly affecting recovery. The decision not to blind the 
attending anesthesiologist was based on patient safety, the fact they were not assessing 
outcomes and the cost savings of not requiring pharmacy to provided blinded syringes of 
study drug. 
The Primary Outcome Measure 
The Digit Symbol Substitution Test, part ofthe WAIS battery of tests was chosen 
as the primary outcome measure in a battery of neuropsychological tests to assess 
recovery of the multi-dimensional area of cognitive function. A baseline or preoperative 
assessment of cognitive function was conducted prior to the administration of either of 
the general anesthetic techniques. This was done to provide a measure of "usual" or 
"normal daily" cognitive function and therefore score on these tests. One would expect, 
with appropriate randomization techniques, that in the long run both groups should have 
comparable preoperative scores and testing for baseline differences should not be 
necessary. In fact, as argued by Altman, statistical comparison of baseline parameter 
distributions across randomized groups should not be done (73). Any differences seen 
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will be due to chance if the randomization has been carried out correctly. However, even 
with proper randomization, in studies of limited size, there remains a chance that baseline 
differences in important parameters may be seen. Such baseline differences have to be 
considered in terms of their clinical (as opposed to statistical) importance, as well as their 
strength of relationship to study outcome when judging their relevance as confounders. 
As the DSST was the primary outcome for the trial, the baseline scores were 
assessed to assure similarity between the two treatment groups. The baseline 
administration ofthe DSST showed a difference of 5.7 symbols coded between the two 
groups prior to any study intervention. This was unexpected, as both groups 
demographically were similar in all respects including age, weight and ASA 
classification. The mean score on the DSST was 58.9 for the control group and 64.6 on 
the midazolam intervention group, for a mean difference of -5.7 (95% CI -11.12 to-
0.46). This confidence interval does not include zero, thus suggesting that the two mean 
group scores on the preoperative DSST are different. There likely would be no way to 
prevent this unexpected finding in the future except to perhaps increase the study sample 
size. 
Such a difference was not seen with the other tools within the 
neuropsychological test battery conducted preoperatively. This may be explained by the 
fact that different neuropsychological tests assess slightly different areas of cognitive 
function. This is the reason why a battery of tests is included. i.e. sensory input, central 
processing, vigilance, coding and motor coordination. 
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The a priori statistical approach to the DSST and TDT data analysis initially was 
to use Students' t test for independent grouped means. Given that the study involved 
repeated measures of the primary and other outcomes, a repeated measures ANOVA was 
arguably a more appropriate test for the primary outcome. Given the baseline difference 
in DSST scores, an Analysis of Covariance (ANCOV A) (repeated measures) with 
baseline value as covariate was employed to assess any impact of this potential 
confounder. These differences were not anticipated a priori and these adjustments to 
statistical approach were determined post hoc. 
Clinically Significant Difference 
This study concluded that based upon a predetermined clinically significant 
difference of 13 on the DSST score there was no difference detected on cognitive 
recovery between the two anesthetic induction techniques. The choice of a clinically 
significant difference of 13 was reassessed after the study completion. This choice of 13 
was based upon the previous studies of Chemik and associates (57) that assessed the level 
of patient sedation 60 minutes after midazolam administration. The lightly sedated group 
had a score of26.7 symbols substituted; heavily sedated 13.7 and placebo (not sedated) 
had 47.3 symbols substituted. On reassessment Chemik's group had a lower baseline 
score than either group in this study's baseline preoperative tests. Review of Chemik' s 
original paper revealed that the 18 subjects enrolled in the study were of similar age 
(mean 34.5 years compared to 32.3 years in the subjects completing this study). The 
DSST administration appeared to be similar over a 90-second period and with different 
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versions used for subsequent administrations. The scoring may have been slightly 
different, as scores appeared to be the number attempted as opposed to the number 
correct in our current study. The number attempted however should have resulted in a 
higher average score compared to the number correct. The reason for the difference from 
our current study baseline is not readily apparent. 
The clinically significant difference was determined to be 13 looking at the 
difference in heavily sedated compared to lightly sedated scores. We chose not to use the 
placebo I no sedation score as we felt that post general anesthesia subjects would likely 
not return to a placebo baseline. In retrospect however we really wanted to assess the 
return of baseline function (equivalent to placebo function) or possibly "street readiness". 
This study may therefore really show the difference of lightly sedated outcomes as 
opposed to return to baseline function. 
A more accurate estimation of "street readiness" might have been to use the 
placebo score compared to the lightly sedated score. The difference between these two 
groups would have yielded a clinically significant difference of 20.6. Recalculation of 
sample size using the larger clinically significant difference of20.6 would result in a 
sample size estimation of 30 subjects per group. To the extent that this argument is valid, 
it further supports the lack of clinically important differences in outcome between study 
groups in the current trial. 
The whole area of neuropsychological testing and assessment of cognitive 
function is obviously an area of clinical and scientific expertise within the Psychology 
discipline. During the initial formative phase of this study members of Memorial and 
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Dalhousie Universities Departments of Psychology were contacted informally to help 
provide input about these cognitive assessments. If I were to conduct future research 
utilizing other areas of expertise, such as the previously mentioned, I would develop a 
formal association with the involved department I content expert and conduct the trial 
utilizing a multi-disciplinary approach. 
Time Period of Study I Thesis Completion 
This study as described in the background chapters was initially developed in 
1994 I 1995 when midazolam was a newly marketed, short acting benzodiazepine. 
Clinical experience within the context of general anesthesia and specifically in a 
coinduction technique was limited. There was little published literature and this was a 
popular topic of discussion and area for proposed research. 
The time from initial development of this study to final presentation was just over 7 
years. First submission of the written thesis requirement for the degree in Master of 
Science was then completed December 2003. As a result of the protracted time 
taken to complete this project several unique issues were encountered. During this time 
period the patent expired on Hoffman LaRoche's proprietary production ofmidazolam 
(Versed®). Generic brands became available, marketing and thus clinical interest 
diminished and funding for such projects was further limited. 
During this time period considerable clinical experience was gained using both 
midazolam and a coinduction technique. Literature searches were repeated at several 
different times throughout the duration of the project. There were no published works 
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found specifically looking at neuropsychological recovery and midazolam coinduction of 
general inhalation anesthesia. Further experience with the coinduction technique seemed 
to support the clinical impression that emergence from anesthesia possibly was delayed, 
but that recovery and discharge were not adversely affected. Thus despite diminished 
clinical interest; the study remained relevant as the question remained unanswered. 
There were numerous clinical trials published looking at very similar questions 
using midazolam as a preoperative sedative and one TIVA coinduction study (50) 
assessing recovery using neuropsychological testing. 
A remarkably similar study by Richardson et al (72) in 1997 assessed midazolam 
"pre-medication effect" on recovery after brief outpatient gynecologic laparoscopic 
surgery using the DSST and TDT as well as the standard markers of postoperative 
recovery. A unique feature of their study that makes it very comparable to the present 
study, and different from the numerous studies looking at midazolam pre-medication, 
was the timing and route of midazolam administration. Most pre-medication trials 
assessing midazolam recovery effects administer the drug either orally or intramuscularly 
at least 30 minutes or earlier preoperatively. Richardson et al administered the 
midazolam dose intravenously and at 10 minutes prior to the induction of general 
inhalation anesthesia. This sequence and timing could very easily be in keeping with a 
coinduction technique. Some authors (71) describe the administration ofmidazolam 
maybe up to ten minutes prior to administration of propofol as achieving the same 
coinduction effect as when given at one minute prior. The conduct of the general 
anesthetic and dose ofmidazolam was also very comparable to the present study. 
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Richardson et al showed midazolam-associated impairment on early assessment ofDSST 
and TDT (15 and 30 minutes) but no difference on either test at 60 minutes. This paper I 
feel supports the present study in that there is no difference in neuropsychological 
recovery as assessed by neuropsychological tests when midazolam is used in very low 
doses as part of a co induction technique (or immediately prior to induction as an 
"intraoperative pre-medication" in the Richardson case). 
SUMMARY OF FINDINGS 
The results of this study indicate no difference in cognitive recovery as assessed 
by neuropsychological tests after a midazolam coinduced technique versus propofol alone 
in short ambulatory gynecologic procedures. This study suggests, but does not prove, 
that there are no clinically important differences within standard parameters of general 
anesthesia such as hemodynamic stability, adverse events, induction reliability, or 
postoperative clinical parameters such as nausea and vomiting or analgesia requirements. 
No practical economically important differences were demonstrated in favour of using 
either technique. Lack of intraoperative recall and rarity of the event prevents any 
comment about potential protective effects of the coinduction technique. Further 
research in these areas of uncertainty needs to be completed before these remaining 
questions can be definitively answered. 
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LITERATURE SEARCH STRATEGY 
National Library of Medicine Pubmed 
1. Midazolam (MeSH) 
AND 
2. Anesthetics, General (MeSH) OR Anesthesia, General (MeSH) OR 
Anesthesia Recovery Period (MeSH) OR Post-operative Period (MeSH) OR 
Post-operative Care (MeSH) OR Post-operative Complications (MeSH) OR 
Post-op*(Textword) OR Anaesthes*(Textword) OR Anesthes*(Textword) 
AND 
3. Cognition (MeSH) OR Neurobehavioral Manifestations (MeSH) OR 
Neuropsychological Tests (MeSH) OR cognit*(Textword) OR Neurobehav* 
(Textword) 
#1 AND #2 AND #3 
Limited to English Language, Human Studies 
ALSO searched Midazolam (MeSH) AND Anesthesia Recovery Period (MeSH) 
• 
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TITLE: 
DISCIPLINE OF ANESTHESIA 
FACULTY OF MEDICINE 
DALHOUSIE UNIVERSITY 
MEMORIAL UNIVERSITY OF NEWFOUNDLAND 
CONSENT TO PARCIPATE IN BIO-MEDICAL RESEARCH 
Neuropsychological Recovery After Midazolam- Propofol 
Coinduced General Anesthesia 
PRINCIPAL 
INVESTIGATOR(S): Dr. Dolores M. McKeen, 
Dept. of Anesthesia 
INTRODUCTION: 
IWK Grace Health Centre 
5850/5980 University A venue 
PO Box 3070, Halifax, NS B3J 3G9 
You have been asked to participate in a research study. Participation in this study is entirely 
voluntary. You may decide not to participate or may withdraw from the study at any time 
without affecting your normal treatment. None of your legal rights are waived and the 
investigator, research doctor and hospital still have their legal and professional responsibilities. 
Confidentiality of all information about you will be maintained by the investigator. You wi II be 
assigned a study number at the time of entry and will not be personally identified on any study 
documents or subsequent publications. The study documents will be locked and only the 
investigators will have access to them. Occasionally the Research Ethics Board may audit the 
records to ensure these standards are met. The investigator will be available during the study at 
all times should you have any problems or questions about the study. 
!.PURPOSE OF THE STUDY 
The purpose of this study is to find out whether it is better to use one drug at its normal 
dose or two drugs at much smaller doses at the start of a general anesthetic. General 
anesthesia means that the patient is completely asleep during the surgery. The drugs 
which will be used, propofol and midazolam, have been used on their own for years to 
make people sleep and they have been used in millions of patients. When these drugs are 
given together it is possible to give much smaller dosages than if they are used alone. We 
want to look at this to see if there are any differences between using one drug or both 
drugs after the operation is over. We need to see if patients are more sleepy or less sleepy 
and see how long it takes to think and talk clearly. We also need to see how well you 
remember and are able to follow simple instructions after your operation is over. 
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2. STUDY DESIGN 
This study is a single centre study and is only being conducted at this hospital. You wi II 
be assigned to receive one drug or two drugs at smaller doses at random. The chance of 
being assigned to one or the other group is equal (i.e. flipping a coin). The drug dosage 
is decided by your anesthetic doctor based upon your weight. Only your anesthetic doctor 
will know what drugs you receive at the start of the anesthetic. The anesthetic doctor 
will know what drug group you are in by taking a numbered envelope from the study 
coordinator. After that you will receive the standard anesthetic drugs to keep you asleep 
until the surgery is over. How well you remember and think will be checked by 
observing you and asking you questions before you go to sleep and after you wake up in 
the recovery room. You will also be asked to complete some simple psychological tests 
using a pencil and paper. This will be done every thirty minutes until you are ready to go 
home. 
3. DURATION AND FORESEEABLE INCONVENIENCES 
This simple testing should take no more than 5 minutes to complete. If you are not 
feeling well enough to answer the questions then you may refuse. It is possible that you 
may have to stay a little longer in the recovery room if it is felt that you are not ready to 
be discharged. It is possible that research may involve risks that are currently unforeseen. 
4. TREATMENTS FOR THOSE NOT ENTERING THE STUDY 
If you decide not to enter this study, you will receive standard treatment. 
Patients may obtain further information about this study and its results once completed 
by contacting the Research Services Office at 428-8765 or the principal investigator at 
the Department of Anesthesia at the IWK Grace at 420-6627. 
Ill 
I -----------the undersigned, agree to my participation in the 
research study described. 
Any questions have been answered and I understand what is involved in the study. I 
realize that participation is voluntary and that there is no guarantee that I will benefit 
from my involvement. I acknowledge that a copy of this form has been given to me. 
(Print Name) (Signature of Participant) (Date) 
(Print Name) (Witness Signature) (Date) 
To be signed by investigator 
To the best of my ability I have fully explained to the subject the nature of this research 
study. I have invited questions and provided answers. I believe that the subject fully 
understands the implications and voluntary nature of the study. 
(Print Name) (Signature of Investigator) (Date) 
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STUDY CODE NUMBER. ____ _ TIME ADMINISTERED·---
The questions below ask you to make a mark on a line relative to how you feel about the 
statements. The is no right or wrong answer- you simply mark the line based on your 
feeling or opinion. 
Example: 
The room is hot. 
If you felt cooler you or lure if you felt 
migltt mark It ere more warm 
____ x _______________________________ x 
Completely 
Disagree 
I.Overall comment on how drowsy you feel. 
Alert 
2. Comment if you feel any confusion. 
Clear 
Headed 
3.Comment on your overall feelings of coordination. 
Well 
Coordinated 
4. Comment on your level of anxiety. 
Calm/ 
Relaxed 
5. Comment on your overall feeling of sedation. 
Wide awake 
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Completely 
Agree 
Extremely tired 
Fuzzy Headed 
Extremely 
Clumsy 
Extremely 
Nervous 
' . 
Almost asleep 
Appendix E 
Letters of Permission 
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FEE-WAIVED PERMISSION AGREEMENT 
This AGREEMENT entered into as of OCTOBER 15, 1999, between The Psychological 
Corporation, a Harcourt Assessment Company, 555 Academic Court, San Antonio, Texas 
78204-2498 (herein the "Publisher") and 
NAME: 
ADDRESS: 
IWK GRACE HEALTH CENTRE FOR CHILDREN, WOMEN & FAMILIES 
5850/5980 University A venue 
P.O. Box 3070 
Halifax, Nova Scotia 83J 3G9 
CANADA 
(herein the "Licensee"), WITNESSETH: 
WHEREAS the Publisher is the copyright owner of the WECHSLER ADULT INTELLIGENCE 
SCALE-REVISED (herein the "Work"); and 
WHEREAS the Licensee wishes to adapt and reproduce four versions of the Digit Symbol 
subtest from the Work for use in Licensee's study about neuropsychological recovery in post 
general anesthesia subjects in which a benzodiazepine has been used for the induction 
sequence compared to those patients who do not receive a benzodiazepine during their 
induction of general anesthesia (herein the "Licensed Uses"). It is understood that no 
commercial use may be made of the Work or the reproduction(s) authorized herein. 
NOW, THEREFORE, the Publisher and the Licensee agree as follows: 
1. The Licensee may either produce, have produced, and/or distribute such reproductions of 
the Work specified above, solely for the Licensed Uses and subject to the terms and 
conditions set forth in this Agreement. 
~ 
2. The Work shall be identified by title on any reproduction unlesp. otherwise expressly 
provided in this Agreement. 
3. The Licensed Uses specifically exclude the right to print, copy, or distribute in any form, or 
to translate, adapt, or revise, or to exhibit, represent, record, or reproduce any portion of 
the Work, either separately or as part of any other larger publication, except as otherwise 
expressly provided herein. 
4. (a) All rights in the Work not granted to the Licensee by this Agreement are expressly 
reserved to the Publisher. 
(b) The License granted herein shall be for a period commencing with the date first stated 
above and terminating OCTOBER 31, 2000, whereupon all of the Licensed Uses shall 
cease. Licensee must obtain written permission for extension of this Agreement. 
(c) Published reports of the Licensed Uses shall not include reproduction of actual test 
items, answers thereto, or normative data obtained during the research unless 
separate permission is granted in an addendum to this Agreement. 
119 
Appendix F 
Standardized Anesthetic Induction Protocol 
and 
Rescue Protocol 
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INDUCTION ALGORITHM 
l.OPEN ENVELOPE -Inside will be the study group assignment 
i.e. GROUP(A) propofol 2mglkg 
GROUP(B)midazolam 0.02mglkg and propofoll mglkg 
2.DRUG DOSAGES-Draw up drug dosages as appropriate for the patient's weight and 
study group assignment (already calculated on the envelope). 
3.MONITORS-Apply usual monitors prior to induction 
i.e. SP02 I ECG I NIBP etc 
4.START INTRA VENOUS-Appropriate size angiocatheter with either free flowing 
normal saline or lactated ringer's solution. 
5.DRUG ADMINISTRATION-Group A and B -fentany12mcglkg over 15 seconds 
-If Group B -midazolam 0.02mg/kg over15seconds 
-Note exact time of administration (2400h) 
MUST WAIT 2 MINUTES 
BEFORE INDUCTION SEQUENCE COMPLETED 
-Propofol- If study Group A-2mg/,kg 
-If study Group B-lmglkg 
6.ASSESS HYPNOSIS-Assess induction in your usual manner 
i.e. ask the patient to 'OPEN YOUR EYES' or 
check eye lash reflex etc. 
IF APNEIC> 15 SECONDS ASSIST VENTILATION 
IF INDUCTION FAILS AFTER 60 SECONDS MAY ADD 
SUPPLEMENTAL PROPOFOL 0.5mg/kg 
IF STILL AWAKE PROPOFOL AS NECESSARY (PROTOCOL FAILURE) 
Note reason why any additional propofol given on group assignment sheet 
121 
7.IF INDUCED- Muscle relaxant of choice 
i.e. Succinylcholine(l.5mglkg) or Rocuronium(0.6mg/kg) 
-Intubate as usual. 
8.MAINTENANCE OF ANESTHESIA- as clinically appro.priate 
i.e.-N20102 -50150% End tidal 
-Sevoflurane- 1-3% End tidal 
-Supplemental FentanyVmuscle relaxant as necessary 
-Naprosyn 500 mg PR or Toradol 30 mg IV unless CII 
-Ondansetron 4 mg if an anti-emetic desired 
9.LABEL ANESTHETIC RECORD- The study number will be on the envelope. Write 
this on the anesthetic record where propofollmidazolam dosages would be recorded. All 
other drugs maybe noted on the anesthetic record. Write the study number and the total 
amount of propofoll midazolam given on the each half of the paper; tear and seal in 
envelope. Leave with chart it will be attached to the consent for immediate unblinding 
and one with study data collection record. 
lO.REVERSAL OF ANESTHESIA -Reversal as necessary 
i.e.- Neostigmine 50 meg/kg I Glycopyrolate O.Olmglkg 
-End tidal Sevoflurane <0.40% 
-Extubate as clinically appropriate 
ie. eye opening I spontaneous respiration I reaching for ETT 
• ll.TRANSFER TO PACU Analgesia and anti-emetic as necessary 
i.e. Prefer Morphine I Ondansetron pm 
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RESCUE PROTOCOL 
Response to surgical stress: 
Blood Pressure: 
Heart rate: 
Somatic: 
Autonomic: 
increase in systolic BP > 30mm Hg above baseline lasting > 1 
minute 
increase in HR > 110 bpm lasting > 1 minute 
limb movement I swallowing I grimacing 
tearing I dilated pupils I diaphoresis 
If these responses are not attributable to hypovolemia they may be treated with increasing 
the end tidal concentration of Seveflurane 1 - 3 % . If then required supplemental 
fentanyl IV may be given as clinically indicated. If the attending Anesthesiologist then 
feels that there is an adequate level of anesthesia and the patient is still hyperdynamic 
they may add a ~ blocker of their choice such as Esmolol or Labetolol. 
Hemodynamic compromise: 
Blood Pressure: 
Heart rate: 
decrease in systolic BP < 90mm Hg or a decrease from baseline 
systolic blood pressure of greater than 30% for> 1 minute. The 
end tidal concentration of Sevoflurane may,be decreased and/or 
vasopressor agent may be given ie. ephedrine/phenylephrine 
decreased heart rate < 40 bpm cholinergic antagonist may be given 
i.e. atropine O.Olmcg/kg 
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APPENDIXG 
Data Collection Record 
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NEUROPSYCHOLOGICAL RECOVERY AFTER 
MIDAZOLAM - PROPOFOL CO INDUCED 
GENERAL ANAESTHESIA 
PATIENT DOCUMENTATION 
AND 
TESTING MATERIALS 
RANDOMIZATION NUMBER : __ _ 
INVESTIGATOR:------
ANAESTHESIOLOGIST --------
RANDOMIZATION # 
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AGE 
WEIGHT----------------
SURGICAL PROCEDURE-----------
TIME INDUCTION STARTED (2400H) -------
TIME OF EXTUBA TIONIEMERGENGE(2400H) ____ _ 
TOTAL LENGTH OF ANAESTHETIC (MINUTES)-----
PERIOPERATIVE DATA 
HEMODYN PRE-OP POST- u 30 
AMIC I:t:l:TUBA TION MINUTES MINUTES 
PROFILE 
HEART 
RATE 
SYSTOLIC 
BP 
DIASTOLIC 
BP 
45 60 90 
MINUTES MINUTES MINUTES 
FAILURE OF INDUCTION?---------------------
PROPOFOL (TOTAL MG DOSE)------- (MCG/KG)----------
FENTANYL (TOTAL MCG DOSE)- ( MCG/KG)----------
MIDAZOLAM (TOTAL MG DOSE)- (MCG/KG)----------
OTHER DRUGS (DOSAGES) GIVEN-------------------
ADVERSE INTRA-OPERATIVE EVENTS? YES OR NO 
EXPLANATION: ________________________ _ 
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POST OPERATIVE I PACU DATA 
TIME TO REACH ALDRETE SCORE 7 OR >(MINUTES)----------
NARCOTICS ADMINISTERED IN PACU?- YES OR NO 
- TOTAL DRUG DOSE GIVEN ____ _ 
ANTI-EMETICS ADMINISTERED IN PACU?- YES OR NO 
- DRUG/ DOSE GIVEN-------
UNABLE TO COMPLETE TESTING AT ANY POINT?- YES OR NO 
ie. PATIENT WITHDRA WL; NAUSEA 
EXPLANATION: ________________________ _ 
NEUROPSYCHOLOGICAL TESTING 
PRE 30 60 90 I20 I 50 
OPERATIVE MINUTE/ MINUTE MINUTE MINUTE MINUTE 
BASELINE I ST MEASURE MEASURE MEASURE MEASURE 
MEASURE 
TREIGERDOT 
TEST 
( #MISSED/42) 
' DIGIT SYMBOL 
SUBSTITUTION 
(#CORRECT/ 
#COMPLETED) 
VISUAL 
ANALOG 
SCORE #I 
#2 
#3 
#4 
#5 
TIME TO DISCHARGE--------
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APPENDIXH 
Budget 
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BUDGET 
The following provides an estimate of the spending budget for this clinical trial. 
Direct Costs 
1. Clinical/Research Fellow Salary 
-$47,809 per annum provided by IWK Grace Board of Directors Fellowship 
-40% research time (.40 x 47,809=19,123.60) No net cost 
2. 
3. 
4. 
Materials/Supplies 
-Computer/Statistical Software 
-Photocopying 
-Secretarial 
-Telephone 
-Literature Search 
-Testing Materials - W AIS kit 
Clinical Presentation/Travel 
Medical Surgical Supplies 
-propofol 20ml $5.52 
-midazolam 2ml $1.07 
Indirect Costs 
-30% of20,323.60 = 6097.08 
-As study is research driven, not industry driven 
This 30% cost is not applicable 
TOTAL 
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3500.00 
500.00 
200.00 
250.00 
50.00 
300.00 
4800.00 
2000.00 
Standard therapy 
should impose no 
cost 
No net cost 
No net cost 
6800.00 
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